<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for fatigue in inflammatory bowel disease - Farrell, D - 2020 | Cochrane Library</title> <meta content="Interventions for fatigue in inflammatory bowel disease - Farrell, D - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012005.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for fatigue in inflammatory bowel disease - Farrell, D - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012005.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012005.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for fatigue in inflammatory bowel disease" name="citation_title"/> <meta content="Dawn Farrell" name="citation_author"/> <meta content="Institute of Technology Tralee" name="citation_author_institution"/> <meta content="dawn.farrell@staff.ittralee.ie" name="citation_author_email"/> <meta content="Micol Artom" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Wladyslawa Czuber‐Dochan" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Lars P Jelsness‐Jørgensen" name="citation_author"/> <meta content="Østfold University College" name="citation_author_institution"/> <meta content="Christine Norton" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Eileen Savage" name="citation_author"/> <meta content="University College Cork" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD012005.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/04/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012005.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012005.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012005.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adalimumab [administration &amp; dosage, adverse effects]; Anti‐Inflammatory Agents [administration &amp; dosage, adverse effects]; Cognitive Behavioral Therapy; Electroacupuncture; Exercise; Fatigue [etiology, *therapy]; Fatty Acids, Omega‐3 [administration &amp; dosage, adverse effects]; Ferric Compounds [adverse effects]; Hematinics [adverse effects]; Inflammatory Bowel Diseases [*complications]; Psychotherapy, Brief; Pyrones [adverse effects]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012005.pub2&amp;doi=10.1002/14651858.CD012005.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="urvLIhM4";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012005\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012005\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","zh_HANS","ru","fr","ms","ja","hr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012005.pub2",title:"Interventions for fatigue in inflammatory bowel disease",firstPublishedDate:"Apr 16, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012005.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012005.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012005.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012005.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012005.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012005.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012005.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012005.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012005.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012005.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7346 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012005.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0137"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-sec-0131"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/appendices#CD012005-sec-0142"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/table_n/CD012005StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/table_n/CD012005StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for fatigue in inflammatory bowel disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#CD012005-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Dawn Farrell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#CD012005-cr-0003">Micol Artom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#CD012005-cr-0004">Wladyslawa Czuber‐Dochan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#CD012005-cr-0005">Lars P Jelsness‐Jørgensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#CD012005-cr-0006">Christine Norton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information#CD012005-cr-0007">Eileen Savage</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information/en#CD012005-sec-0150">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 April 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012005.pub2">https://doi.org/10.1002/14651858.CD012005.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012005-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012005-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012005-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012005-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012005-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012005-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012005-abs-0001" lang="en"> <section id="CD012005-sec-0001"> <h3 class="title" id="CD012005-sec-0001">Background</h3> <p>Inflammatory bowel disease (IBD) is an umbrella term used to describe a group of chronic, progressive inflammatory disorders of the digestive tract. Crohn's disease and ulcerative colitis are the two main types. Fatigue is a common, debilitating and burdensome symptom experienced by individuals with IBD. The subjective, complex nature of fatigue can often hamper its management. The efficacy and safety of pharmacological or non‐pharmacological treatments for fatigue in IBD is not yet established through systematic review of studies. </p> </section> <section id="CD012005-sec-0002"> <h3 class="title" id="CD012005-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of pharmacological and non‐pharmacological interventions for managing fatigue in IBD compared to no treatment, placebo or active comparator. </p> </section> <section id="CD012005-sec-0003"> <h3 class="title" id="CD012005-sec-0003">Search methods</h3> <p>A systematic search of the databases Embase, MEDLINE, Cochrane Library, CINAHL, PsycINFO was undertaken from inception to July 2018. A top‐up search was run in October 2019. We also searched the Cochrane IBD Group Specialized Register, the Cochrane Central Register of Controlled Trials, ongoing trials and research registers, conference abstracts and reference lists for potentially eligible studies. </p> </section> <section id="CD012005-sec-0004"> <h3 class="title" id="CD012005-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of pharmacological and non‐pharmacological interventions in children or adults with IBD, where fatigue was assessed as a primary or secondary outcome using a generic or disease‐specific fatigue measure, a subscale of a larger quality of life scale or as a single‐item measure, were included. </p> </section> <section id="CD012005-sec-0005"> <h3 class="title" id="CD012005-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened search results and four authors extracted and assessed bias independently using the Cochrane 'Risk of bias' tool. The primary outcome was fatigue and the secondary outcomes included quality of life, adverse events (AEs), serious AEs and withdrawal due to AEs. Standard methodological procedures were used. </p> </section> <section id="CD012005-sec-0006"> <h3 class="title" id="CD012005-sec-0006">Main results</h3> <p>We included 14 studies (3741 participants): nine trials of pharmacological interventions and five trials of non‐pharmacological interventions. Thirty ongoing studies were identified, and five studies are awaiting classification. Data on fatigue were available from nine trials (1344 participants). In only four trials was managing fatigue the primary intention of the intervention (electroacupuncture, physical activity advice, cognitive behavioural therapy and solution‐focused therapy). </p> <p><b>Electroacupuncture</b><br/> Fatigue was measured with Functional Assessment of Chronic Illness Therapy ‐ Fatigue (FACIT‐F) (scores range from 0 to 52). The FACIT‐F score at week eight was 8.00 points higher (better) in participants receiving electroacupuncture compared with no treatment (mean difference (MD) 8.00, 95% CI 6.45 to 9.55; 1 RCT; 27 participants; low‐certainty evidence). Results at week 16 could not be calculated. FACIT‐F scores were also higher with electroacupuncture compared to sham electroacupuncture at week eight (MD 5.10, 95% CI 3.49 to 6.71; 1 RCT; 30 participants; low‐certainty evidence) but not at week 16 (MD 2.60, 95% CI 0.74 to 4.46; 1 RCT; 30 participants; low‐certainty evidence). No adverse events were reported, except for one adverse event in the sham electroacupuncture group. </p> <p><b>Cognitive behavioural therapy (CBT) and solution‐focused therapy</b><br/> Compared with a fatigue information leaflet, the effects of CBT on fatigue are very uncertain (Inflammatory Bowel Disease‐Fatigue (IBD‐F) section I: MD ‐2.16, 95% CI ‐6.13 to 1.81; IBD‐F section II: MD ‐21.62, 95% CI ‐45.02 to 1.78; 1 RCT, 18 participants, very low‐certainty evidence). The efficacy of solution‐focused therapy on fatigue is also very uncertain, because standard summary data were not reported (1 RCT, 98 participants). </p> <p><b>Physical activity advice</b><br/> One 2 x 2 factorial trial (45 participants) found physical activity advice may reduce fatigue but the evidence is very uncertain. At week 12, compared to a control group receiving no physical activity advice plus omega 3 capsules, FACIT‐F scores were higher (better) in the physical activity advice plus omega 3 group (FACIT‐F MD 6.40, 95% CI ‐1.80 to 14.60, very low‐certainty evidence) and the physical activity advice plus placebo group (FACIT‐F MD 9.00, 95% CI 1.64 to 16.36, very low‐certainty evidence). Adverse events were predominantly gastrointestinal and similar across physical activity groups, although more adverse events were reported in the no physical activity advice plus omega 3 group. </p> <p><b>Pharmacological interventions</b><br/> Compared with placebo, adalimumab 40 mg, administered every other week ('eow') (only for those known to respond to adalimumab induction therapy), may reduce fatigue in patients with moderately‐to‐severely active Crohn's disease, but the evidence is very uncertain (FACIT‐F MD 4.30, 95% CI 1.75 to 6.85; very low‐certainty evidence). The adalimumab 40 mg eow group was less likely to experience serious adverse events (OR 0.56, 95% CI 0.33 to 0.96; 521 participants; moderate‐certainty evidence) and withdrawal due to adverse events (OR 0.48, 95%CI 0.26 to 0.87; 521 participants; moderate‐certainty evidence). </p> <p>Ferric maltol may result in a slight increase in fatigue, with better SF‐36 vitality scores reported in the placebo group compared to the treatment group following 12 weeks of treatment (MD ‐9.31, 95% CI ‐17.15 to ‐1.47; 118 participants; low‐certainty evidence). There may be little or no difference in adverse events (OR 0.55, 95% CI 0.26 to 1.18; 120 participants; low‐certainty evidence) </p> </section> <section id="CD012005-sec-0007"> <h3 class="title" id="CD012005-sec-0007">Authors' conclusions</h3> <p>The effects of interventions for the management of fatigue in IBD are uncertain. No firm conclusions regarding the efficacy and safety of interventions can be drawn. Further high‐quality studies, with a larger number of participants, are required to assess the potential benefits and harms of therapies. Future studies should assess interventions specifically designed for fatigue management, targeted at selected IBD populations, and measure fatigue as the primary outcome. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012005-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012005-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012005-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012005-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012005-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012005-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012005-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012005-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012005-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012005-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012005-abs-0003" lang="en"> <h3>Treatments for extreme tiredness and lack of energy (fatigue) in inflammatory bowel disease </h3> <p><b>Review question</b> </p> <p>What are the effects of drug and non‐drug treatments on fatigue in individuals with inflammatory bowel disease (IBD) compared to no treatment, placebo (e.g. a sugar pill) or active comparator (e.g. a known effective treatment)? </p> <p><b>Background</b> </p> <p>IBD is a life‐long illness that causes inflammation and ulceration in the gut. Crohn's disease and ulcerative colitis are the two main types of IBD. People living with IBD often experience fatigue, which can be burdensome and negatively impact on their quality of life. Different treatments, such as medications and exercise, may improve fatigue. However, it is unclear what the effects of such treatments on fatigue in IBD are. This review presents the available evidence of the effectiveness of treatments on fatigue in IBD. </p> <p><b>Search date</b> </p> <p>Extensive searches were undertaken from inception up to July 2018. A top‐up search was run in October 2019. </p> <p><b>Study characteristics</b> </p> <p>Fourteen studies (3741 participants with IBD) met the inclusion criteria. Nine different drug trials, four non‐drug trials and one multimodular trial were included in the review. Thirty ongoing studies were also identified and five studies are awaiting classification. In only four trials was managing fatigue the aim of the intervention. In the remaining trials the interventions were aimed at managing other symptoms, including fatigue. Data on fatigue were not available for the fourteen trials, therefore, the findings of this review are based on 1344 participants in nine trials. Most studies were small in size and had low or very low quality of evidence. </p> <p><b>Key results and quality of evidence</b> </p> <p>The evidence suggests electroacupuncture may result in a large reduction in fatigue compared to control and sham electroacupuncture, however, the overall certainty of the evidence is low due to sparse data. No adverse events were reported, except for one adverse event in the sham acupuncture group. </p> <p>We are very uncertain about the effect of cognitive behavioural therapy and solution‐focused therapy on fatigue, as the quality of the evidence is very low. </p> <p>One small study found that physical activity advice plus omega 3 and physical activity advice plus placebo may reduce fatigue compared to no physical activity advice plus omega 3. Adverse events were similar across physical activity groups, although more adverse events were reported in the no physical activity advice plus omega 3 group. Adverse events were mainly mild gastrointestinal events like diarrhoea and bloating </p> <p>Compared with placebo, the drug alimumab 40 mg, administered every other week, may reduce fatigue in patients with moderately‐to‐severely active Crohn's disease, who are already known to respond to adalimumab treatment, but the evidence is very uncertain. People taking adalimumab 40 mg weekly were less like to experience serious adverse events or withdraw from the trial due to adverse events, compared to people taking placebo. </p> <p>The evidence suggests ferric maltol results in a slight increase in fatigue in participants with Crohn's disease and ulcerative colitis, in remission or with mild‐to‐moderate disease activity. Following 12 weeks of ferric maltol treatment, less fatigue was reported in the placebo group compared to the treatment group, however, the quality of evidence is low. </p> <p><b>Conclusion</b> </p> <p>The effects of interventions for the management of fatigue on IBD are uncertain, with limited evidence available. No firm conclusions regarding the benefits and harms (e.g. side effects) can be drawn, Further high‐quality studies, with a larger number of participants, are needed to determine the potential effect of treatments on fatigue in IBD. Future studies should assess fatigue as a primary outcome, be specifically designed for fatigue management and targeted at specific IBD populations. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012005-sec-0137" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012005-sec-0137"></div> <h3 class="title" id="CD012005-sec-0138">Implications for practice</h3> <section id="CD012005-sec-0138"> <p>The data were not sufficient or of high enough quality to identify specific interventions that might be associated with a positive effect on fatigue management in individuals with IBD. Limited available data, the heterogeneity of studies and fatigue not being the primary endpoint of most studies are limitations of the evidence base. Furthermore, the optional duration and suitability of interventions remains unclear. Biologic therapy (adalimumab 40 mg administered every other week only for those known to respond to adalimumab induction therapy) may reduce fatigue and iron therapy (ferric maltol) may result in a slight increase in fatigue, however the evidence is very uncertain. Non‐pharmacological treatments, such as electroacupuncture and physical activity may reduce fatigue in individuals with IBD. The small sample sizes and high risk of bias in these trials means the benefit of these treatments is uncertain and suggests that further research is needed. </p> </section> <h3 class="title" id="CD012005-sec-0139">Implications for research</h3> <section id="CD012005-sec-0139"> <p>Research aimed at managing fatigue as a major IBD burden is lacking and hopefully, this review will act as a catalyst to initiate these studies. To date, there is a lack of high‐quality research evaluating the effect of interventions on fatigue in IBD, despite the high prevalence and burdensome nature of this symptom. The evidence in this review applies to a broad range of therapies (pharmacological and non‐pharmacological). Further investigation is warranted. Reporting in some of the trials was insufficient to assess the efficacy and safety of some therapies. This review focused on presenting clinically important findings, however, at times, it was difficult to determine if the observed improvements in fatigue on some scales (IBDF, total fatigue score, average frequency of tiredness, average severity of tiredness) were clinically meaningful. There is need for clearly defined minimal clinically important difference thresholds for fatigue measures in the IBD population. </p> <p>There is a need for considerably more robust, well‐designed randomised controlled trials to identify effective treatments for fatigue in IBD. Further research is required to test interventions specifically designed to manage fatigue in patients with IBD. In order to identify the types and specific elements of interventions that are effective in improving fatigue, there should be more research targeted at selected IBD populations. This will identify subgroups of patients most likely to benefit from certain interventions. Alternative non‐pharmacological treatments found to be effective in other chronic illnesses, such as educational interventions, warrant investigation in the IBD population. Future research needs to use validated generic and/or disease‐specific measures of fatigue and measure the long‐term effects of interventions. Trials should recruit a sufficient sample size, as predetermined by a power calculation, in order to be adequately powered to detect differences between intervention and control groups. Methodological standards of clinical trials, particularly for non‐pharmacological interventions, need to be improved. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012005-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012005-sec-0036"></div> <div class="table" id="CD012005-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Electroacupuncture compared to no treatment for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Electroacupuncture compared to control for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> electroacupuncture<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with electroacupuncture</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐Fatigue<br/> follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 25.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8 higher<br/> (6.45 higher to 9.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue. The difference in fatigue levels at the week‐16 follow‐up could not be calculated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ‐9<br/> follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 57.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.5 higher<br/> (3.37 higher to 5.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ‐9 scores ranged from 9 to 63, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small and the confidence interval was wide. </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision as the number of participants was small and an unvalidated outcome measure was used. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012005-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> electroacupuncture<br/> <b>Comparison:</b> sham electroacupuncture </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham electroacupuncture</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with electroacupuncture</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 28.8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.6 higher<br/> (0.74 higher to 4.46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ‐9<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 58.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.2 higher<br/> (0.98 higher to 3.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ‐9 scores ranged from 9 to 63, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.32<br/> (0.01 to 8.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One adverse event was reported in the sham acupuncture group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.32<br/> (0.01 to 8.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was one withdrawal due to adverse events in the sham acupuncture group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision; small number of participants from a single study and the confidence interval was wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012005-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CBT with therapist support compared to fatigue information leaflet only for participants with IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>CBT with therapist support compared to fatigue information leaflet only for participants with IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> CBT with therapist support<br/> <b>Comparison:</b> fatigue information leaflet only </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fatigue information leaflet only</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT with therapist support</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section I<br/> follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 9.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.16 lower<br/> (6.13 lower to 1.81 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section II<br/> Scale from: 0 to 120<br/> follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 47.33</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 21.62 lower<br/> (45.02 lower to 1.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: UK‐IBDQ<br/> follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 95.7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.19 higher<br/> (9.32 lower to 9.7 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK‐IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision; small number of participants from a single study and the confidence interval was wide. </p> <p><sup>2</sup> Downgraded one level due to risk of bias in blinding of participants and personnel and blinding in outcome assessment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012005-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> physical activity advice plus omega 3<br/> <b>Comparison:</b> no physical activity advice plus omega 3 </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no physical activity advice plus omega 3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with physical activity advice plus omega 3</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.4 higher<br/> (1.8 lower to 14.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: MFI<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 14.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.5 lower<br/> (3.88 lower to 2.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI scores ranged from 0 to 84, with higher scores indicating greater fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section I<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 9.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.1 lower<br/> (6.67 lower to 0.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section II<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 34.8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 13.1 lower<br/> (29.37 lower to 3.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life assessed with: IBDQ</p> <p>follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean QoL score was 167</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 4.00 higher (18.46 lower to 26.46 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: Medication diary<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were five reported adverse events in the physical activity advice plus omega 3 group and 14 adverse events in the control group, including epigastric pain, bloating, and nausea and vomiting. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were recorded in the medication diary and assessed by the researcher during the 6 follow‐up contact time points. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small, confidence interval was wide and pre‐protocol analyses used. </p> <p><sup>2</sup> Downgraded one level as high risk of bias for blinding of participants and personnel and blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012005-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> physical activity advice plus placebo<br/> <b>Comparison:</b> no physical activity advice plus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no physical activity advice plus placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with physical activity advice plus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 38.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.7 higher<br/> (2.48 lower to 7.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: MFI<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 15.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.6 lower<br/> (4.7 lower to 0.5 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI scores ranged from 0 to 84, with higher scores indicating greater fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section I<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 8.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.7 lower<br/> (4.04 lower to 0.64 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section II<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 27.9</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.5 lower<br/> (21.57 lower to 4.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: assessed with: Medication diary<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were four reported adverse events in the physical activity advice plus placebo group and five reported adverse events in the no physical activity advice plus placebo group, including epigastric pain, diarrhoea, bloating, nausea and vomiting, headache, and molluscum </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were recorded in the medication diary and assessed by the researcher during the 6 follow‐up contact time points. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small, the confidence interval was wide and per protocol analyses used. </p> <p><sup>2</sup> Downgraded one level due to high risk of bias for blinding of participants and personnel and blinding of outcome assessments. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012005-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> physical activity advice plus placebo<br/> <b>Comparison:</b> no physical activity advice plus omega 3 </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no physical activity advice plus omega 3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with physical activity advice plus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 9 higher<br/> (1.64 higher to 16.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: MFI<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 14.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.4 lower<br/> (4.39 lower to 1.59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI scores ranged from 0 to 84, with higher scores indicating greater fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBDF Section 1<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 9.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.8 lower<br/> (5.93 lower to 0.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBDF Section 2<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 34.8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 15.4 lower<br/> (30.51 lower to 0.29 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: assessed with: Medication diary<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were four reported adverse events in the physical activity advice plus placebo group and fourteen reported adverse events in the no physical activity advice plus omega 3 group, including epigastric pain, diarrhoea, bloating, nausea and vomiting, IBD flare, joint pain, and ankle injury. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were recorded in the medication diary and assessed by the researcher during the 6 follow‐up contact time points. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small, confidence interval was wide and per protocol analyses used. </p> <p><sup>2</sup> Downgraded one level due to high risk of bias for blinding of participants and personnel and blinding of outcome assessments. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012005-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012005-sec-0037"></div> <section id="CD012005-sec-0038"> <h3 class="title" id="CD012005-sec-0038">Description of the condition</h3> <p>Inflammatory bowel disease (IBD) represents a group of chronic, progressive, complex inflammatory disorders of the digestive tract, and approximately five million people have a diagnosis of IBD worldwide (<a href="./references#CD012005-bbs2-0152" title="WilsonB , LönnforsS , VermeireS . The true impact of IBD: a European Crohn's and Ulcerative Colitis patient life. IMPACT Survey 2010‐2011. 21st Century Challenges Autoimmune Diseases. European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), Brussels, Belgium; European Crohn’s and Colitis Organization (ECCO); 2012; Vienna, Austria. 2012. ">Wilson 2012</a>). Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of IBD. Both diseases are characterised by periods of relapse and remission, and they have overlapping and distinct pathological and clinical features (<a href="./references#CD012005-bbs2-0088" title="BernsteinC , FriedM , KrabshuisJH , CohenH , EliakimR , FedailS , et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflammatory Bowel Diseases2010;16(1):112‐24. ">Bernstein 2010</a>). Individuals with CD or UC experience a wide range of symptoms including diarrhoea, abdominal pain, fatigue, weight loss and rectal bleeding (<a href="./references#CD012005-bbs2-0097" title="CroninCC , ShanahanF . Understanding symptoms and signs in inflammatory bowel disease. In: TarganSR , ShanahanF , KarpLC editor(s). Inflammatory Bowel Disease: From Bench to Bedside. Springer, 2005:253‐67. ">Cronin 2005</a>). </p> <p>Fatigue has been identified as one of the most burdensome symptoms experienced by individuals with IBD (<a href="./references#CD012005-bbs2-0109" title="FarrellD . Symptom Burden in Individuals with Inflammatory Bowel Disease: a Mixed Methods Study [PhD thesis]. University College Cork, Ireland, 2013. ">Farrell 2013</a>; <a href="./references#CD012005-bbs2-0110" title="FarrellD , SavageE , McCarthyG . Self‐reported symptom burden in individuals with inflammatory bowel disease. Journal of Crohn’s and Colitis2016;10(3):315‐22. ">Farrell 2016</a>). This symptom is particularly problematic during active disease with prevalence rates as high as 86% reported (<a href="./references#CD012005-bbs2-0149" title="VanLangenbergDR , GibsonPR . Systematic review: fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2010;32(2):131‐43. ">Van Langenberg 2010</a>). However, patients also continue to experience fatigue during remission (41% to 48%) (<a href="./references#CD012005-bbs2-0149" title="VanLangenbergDR , GibsonPR . Systematic review: fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2010;32(2):131‐43. ">Van Langenberg 2010</a>). These high rates of fatigue are comparable with rates experienced by oncology patients (<a href="./references#CD012005-bbs2-0146" title="StoneP , MintonO . Cancer‐related fatigue. European Journal of Cancer2008;44(8):1097‐104. ">Stone 2008</a>). Furthermore, a study by <a href="./references#CD012005-bbs2-0125" title="Jelsness‐JørgensenL‐P , BernklevT , HenriksenM , TorpR , MoumBA . Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. Inflammatory Bowel Diseases2011;17(7):1564‐72. ">Jelsness‐Jørgensen 2011a</a> found that chronic fatigue, defined as substantial fatigue with duration of more than six months, was significantly more common in patients with UC and CD than healthy controls. In addition, patients with IBD experiencing chronic fatigue have significantly higher levels of disease‐related worries and concerns (<a href="./references#CD012005-bbs2-0124" title="Jelsness‐JørgensenL‐P , BernklevT , HenriksenM , TorpR , MoumB . Chronic fatigue is associated with increased disease‐related worries and concerns in inflammatory bowel disease. World Journal of Gastroenterology2012;18(5):445‐52. ">Jelsness‐Jørgensen 2012</a>). Reduced energy level is a leading and consistent concern among individuals with IBD (<a href="./references#CD012005-bbs2-0089" title="CasatiJ , TonerBB , DeRooyEC , DrossmanDA , MaunderRG . Concerns of patients with inflammatory bowel disease: a review of emerging themes. Digestive Diseases and Sciences2000;45(1):26‐31. ">Casati 2000</a>; <a href="./references#CD012005-bbs2-0090" title="CasellasF , López‐VivancosJ , BadiaX , VilasecaJ , MalageladaJR . Influence of inflammatory bowel disease on different dimensions of quality of life. European Journal of Gastroenterology and Hepatology2001;13(5):567‐72. ">Casellas 2001</a>; <a href="./references#CD012005-bbs2-0104" title="DeRooyEC , TonerBB , MaunderRG , GreenbergGR , BaronD , SteinhartAH , et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. American Journal of Gastroenterology2001;96(6):1816‐21. ">De Rooy 2001</a>; <a href="./references#CD012005-bbs2-0107" title="DrossmanDA , PatrickDL , MitchellCM , ZagamiEA , AppelbaumMI . Health‐related quality of life in inflammatory bowel disease. Digestive Diseases and Sciences1989;34(9):1379‐86. ">Drossman 1989</a>; <a href="./references#CD012005-bbs2-0123" title="Jelsness‐JørgensenL‐P , MoumB , BernklevT . Worries and concerns among inflammatory bowel disease patients followed prospectively over one year. Gastroenterology Research and Practice2011;2011:492034. [DOI: 10.1155/2011/492034] ">Jelsness‐Jørgensen 2011b</a>). In addition, IBD‐related fatigue negatively impacts on health‐related quality of life and activities of daily living (<a href="./references#CD012005-bbs2-0101" title="Czuber‐DochanW , ReamE , NortonC . Review article: description and management of fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2013;37(5):505‐16. ">Czuber‐Dochan 2013a</a>; <a href="./references#CD012005-bbs2-0102" title="Czuber‐DochanW , DibleyLB , TerryH , ReamE , NortonC . The experience of fatigue in people with inflammatory bowel disease: an exploratory study. Journal of Advanced Nursing2013;69(9):1987‐99. ">Czuber‐Dochan 2013b</a>; <a href="./references#CD012005-bbs2-0117" title="GraffLA , VincentN , WalkerJR , ClaraI , CarrR , EdigerJ , et al. A population‐based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflammatory Bowel Diseases2011;17(9):1882‐9. ">Graff 2011</a>; <a href="./references#CD012005-bbs2-0126" title="Jelsness‐JørgensenL‐P , BernklevT , HenriksenM , TorpR , MoumBA . Chronic fatigue is associated with impaired health‐related quality of life in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2011;33(1):106‐14. ">Jelsness‐Jørgensen 2011c</a>; <a href="./references#CD012005-bbs2-0132" title="MinderhoudIM , OldenburgB , VanDamPS , VanBerge HenegouwenGP . High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. American Journal of Gastroenterology2003;98(5):1088‐93. ">Minderhoud 2003</a>; <a href="./references#CD012005-bbs2-0136" title="OpheimR , FagermoenMS , BernklevT , Jelsness‐JorgensenL‐P , MoumB . Fatigue interference with daily living among patients with inflammatory bowel disease. Quality of Life Research2014;23(2):707‐17. ">Opheim 2014</a>). Despite the high prevalence of chronic fatigue in IBD, this subjective complaint remains largely ignored in the IBD literature, particularly regarding the investigation of underlying mechanisms and treatment strategies for fatigue. </p> <p>Fatigue has been difficult to delineate due to the subjective nature of the symptom. In chronic diseases, fatigue has been defined as a ‘persistent, overwhelming sense of tiredness, weakness or exhaustion resulting in a decreased capacity for physical and mental work’ (<a href="./references#CD012005-bbs2-0106" title="DittnerAJ , WesselySC , BrownRG . The assessment of fatigue: a practical guide for clinicians and researchers. Journal of Psychosomatic Research2004;56(2):157‐70. ">Dittner 2004</a>; <a href="./references#CD012005-bbs2-0128" title="LaiJ‐S , CellaD , ChangC‐H , BodeRK , HeinemannAW . Item banking to improve, shorten and computerize self‐reported fatigue: an illustration of steps to create a core item bank from the FACIT‐Fatigue Scale. Quality of Life Research2003;12(5):485‐501. ">Lai 2003</a>). Although some studies have continued to measure fatigue in IBD from a unidimensional perspective, for example, in terms of prevalence (<a href="./references#CD012005-bbs2-0132" title="MinderhoudIM , OldenburgB , VanDamPS , VanBerge HenegouwenGP . High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. American Journal of Gastroenterology2003;98(5):1088‐93. ">Minderhoud 2003</a>), or severity (<a href="./references#CD012005-bbs2-0136" title="OpheimR , FagermoenMS , BernklevT , Jelsness‐JorgensenL‐P , MoumB . Fatigue interference with daily living among patients with inflammatory bowel disease. Quality of Life Research2014;23(2):707‐17. ">Opheim 2014</a>), it is now generally accepted that fatigue is a multidimensional phenomenon, characterised by diminished perceived physical energy, mental capacity and psychological status (<a href="./references#CD012005-bbs2-0149" title="VanLangenbergDR , GibsonPR . Systematic review: fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2010;32(2):131‐43. ">Van Langenberg 2010</a>). These physical, cognitive and affective dimensions of fatigue form the components of generic fatigue measures such as the Multidimensional Fatigue Inventory. More recent studies have assessed fatigue using multiple dimensions, such as severity/intensity, frequency, duration, distress and impact (<a href="./references#CD012005-bbs2-0085" title="BagerP , BefritsR , WikmanO , LindgrenS , MoumB , HjortswangH , et al. Fatigue in out‐patients with inflammatory bowel disease is common and multifactorial. Alimentary Pharmacology and Therapeutics2012;35(1):133‐41. ">Bager 2012</a>; <a href="./references#CD012005-bbs2-0101" title="Czuber‐DochanW , ReamE , NortonC . Review article: description and management of fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2013;37(5):505‐16. ">Czuber‐Dochan 2013a</a>). Furthermore, the characteristics of fatigue are captured to varying degrees by the diverse range of symptom and quality of life measures available, including both generic and disease‐specific indices (<a href="./references#CD012005-bbs2-0100" title="Czuber‐DochanW , NortonC , BassettP , BerlinerS , BredinF , DarvellM , et al. Development and psychometric testing of inflammatory bowel disease fatigue (IBD‐F) patient self‐assessment scale. Journal of Crohn's and Colitis2014;8(11):1398‐406. ">Czuber‐Dochan 2014c</a>; <a href="./references#CD012005-bbs2-0121" title="HjollundNH , AndersenJH , BechP . Assessment of fatigue in chronic disease: a bibliographic study of fatigue measurement scales. Health Quality Life Outcomes2007;5(1):12. ">Hjollund 2007</a>). It is known that IBD‐related fatigue is associated with a number of physical, psychological and situational factors, with increased disease activity, depression, anxiety and stress found to be consistently associated with greater levels of fatigue (<a href="./references#CD012005-bbs2-0101" title="Czuber‐DochanW , ReamE , NortonC . Review article: description and management of fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2013;37(5):505‐16. ">Czuber‐Dochan 2013a</a>). As a result, the nonspecific, subjective, complex nature of fatigue can often hamper the management of this burdensome symptom. Although healthcare professionals perceive fatigue as an important and problematic symptom in patients with IBD, the management of fatigue remains poorly understood (<a href="./references#CD012005-bbs2-0098" title="Czuber‐DochanW , NortonC , BredinF , DarvellM , NathanI , TerryH . Healthcare professionals' perceptions of fatigue experienced by people with IBD. Journal of Crohn's and Colitis2014;8(8):835‐44. ">Czuber‐Dochan 2014a</a>). Healthcare professionals have identified the need for more information and education to facilitate the management of fatigue in clinical practice (<a href="./references#CD012005-bbs2-0099" title="Czuber‐DochanW , NortonC , BredinF , ForbesA , NathanI , BerlinerS , et al. Assessing fatigue in patients with inflammatory bowel disease. Gastrointestinal Nursing2014;12(8):13‐21. ">Czuber‐Dochan 2014b</a>). However, the effectiveness of interventions for fatigue in IBD has not been systematically reviewed. </p> </section> <section id="CD012005-sec-0039"> <h3 class="title" id="CD012005-sec-0039">Description of the intervention</h3> <p>Given the multidimensional nature of fatigue involving biological, psychosocial, and behavioural processes (<a href="./references#CD012005-bbs2-0136" title="OpheimR , FagermoenMS , BernklevT , Jelsness‐JorgensenL‐P , MoumB . Fatigue interference with daily living among patients with inflammatory bowel disease. Quality of Life Research2014;23(2):707‐17. ">Opheim 2014</a>), pharmacological and non‐pharmacological interventions either alone or in combination may help to improve or alleviate fatigue. Pharmacological interventions involve the administration of drugs through any route. Non‐pharmacological interventions may include any type of physical, psychological, psychosocial, behavioural or educational interventions. Interventions have been developed to address the problem of IBD‐related fatigue either directly or indirectly. For example, this could be directly in terms of an intervention specifically aimed at improving or alleviating fatigue (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), or indirectly in terms of an intervention aimed at the overall management of IBD which assesses fatigue as a secondary outcome (<a href="./references#CD012005-bbs2-0113" title="Garcia‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">Garcia‐Vega 2004</a>). However, there is uncertainty regarding the effectiveness of these interventions in alleviating fatigue, particularly in the long term. </p> </section> <section id="CD012005-sec-0040"> <h3 class="title" id="CD012005-sec-0040">How the intervention might work</h3> <p>Interventions may address the physical, psychological or situational factors contributing to fatigue. It is important that these contributory factors are clearly understood in order to target interventions effectively. For example, where fatigue is related to a physical problem such as anaemia, iron supplements or intravenous iron therapy may be beneficial. Alternatively, if the physical issue is inflammation due to a disease flare, a pharmacological intervention such as biological therapy may be valuable. If altered mood is a factor contributing to fatigue, psychosocial behavioural interventions may be valuable. Often fatigue is influenced by a number of factors, therefore a multicomponent intervention may be an effective approach. </p> </section> <section id="CD012005-sec-0041"> <h3 class="title" id="CD012005-sec-0041">Why it is important to do this review</h3> <p>The incidence of IBD has been increasing over time (<a href="./references#CD012005-bbs2-0134" title="MolodeckyNA , SoonIS , RabiDM , GhaliWA , FerrisM , ChernoffG , et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;142(1):46‐54.e42. ">Molodecky 2012</a>). Fatigue has been identified as the most burdensome symptom experienced by individuals with IBD that impacts negatively on all aspects of daily life (<a href="./references#CD012005-bbs2-0109" title="FarrellD . Symptom Burden in Individuals with Inflammatory Bowel Disease: a Mixed Methods Study [PhD thesis]. University College Cork, Ireland, 2013. ">Farrell 2013</a>; <a href="./references#CD012005-bbs2-0110" title="FarrellD , SavageE , McCarthyG . Self‐reported symptom burden in individuals with inflammatory bowel disease. Journal of Crohn’s and Colitis2016;10(3):315‐22. ">Farrell 2016</a>; <a href="./references#CD012005-bbs2-0152" title="WilsonB , LönnforsS , VermeireS . The true impact of IBD: a European Crohn's and Ulcerative Colitis patient life. IMPACT Survey 2010‐2011. 21st Century Challenges Autoimmune Diseases. European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), Brussels, Belgium; European Crohn’s and Colitis Organization (ECCO); 2012; Vienna, Austria. 2012. ">Wilson 2012</a>). Due to the increasing prevalence, debilitating character and unknown aetiology, interventions for IBD‐related fatigue have received increased attention. Recently, in other chronic conditions which are associated with fatigue, there has been an increase in the number of Cochrane reviews on interventions for fatigue. For example, for cancer‐related fatigue, there are reviews assessing the effect of pharmaceutical interventions (<a href="./references#CD012005-bbs2-0133" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer‐related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] ">Minton 2010</a>), blood transfusions (<a href="./references#CD012005-bbs2-0139" title="PrestonNJ , HurlowA , BrineJ , BennettMI . Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009007.pub2] ">Preston 2012</a>), exercise (<a href="./references#CD012005-bbs2-0095" title="CrampF , Byron‐DanielJ . Exercise for the management of cancer‐related fatigue in adults. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD006145.pub3] ">Cramp 2012</a>), education (<a href="./references#CD012005-bbs2-0086" title="BennettS , PurcellA , MeredithP , BellerE , HainesT , FlemingJ . Educational interventions for the management of cancer‐related fatigue in adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD008144] ">Bennett 2009</a>), and psychosocial interventions (<a href="./references#CD012005-bbs2-0115" title="GoedendorpMM , GielissenMFM , VerhagenCAHHVM , BleijenbergG . Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006953.pub2] ">Goedendorp 2009</a>). However, unlike cancer and other chronic conditions, such as multiple sclerosis (<a href="./references#CD012005-bbs2-0118" title="HeineM , Van dePortI , RietbergMB , VanWegenEEH , KwakkelG . Exercise therapy for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD009956.pub2] ">Heine 2015</a>), peripheral neuropathy (<a href="./references#CD012005-bbs2-0151" title="WhiteCM , VanDoornPA , GarssenMPJ , StockleyRC . Interventions for fatigue in peripheral neuropathy. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008146.pub2] ">White 2014</a>) and rheumatoid arthritis (<a href="./references#CD012005-bbs2-0096" title="CrampF , HewlettS , AlmeidaC , KirwanJR , ChoyEHS , ChalderT , et al. Non‐pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008322.pub2] ">Cramp 2013</a>), no systematic review has been undertaken to assess the effects of interventions for fatigue in IBD. It is therefore proposed to systematically review and synthesise existing evidence on the effects of interventions for the management of fatigue in individuals with IBD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012005-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012005-sec-0042"></div> <p>The aim of this review is to assess the efficacy and safety of pharmacological and non‐pharmacological interventions on fatigue in IBD compared to no treatment, placebo or active comparator. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012005-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012005-sec-0043"></div> <section id="CD012005-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012005-sec-0045"> <h4 class="title">Types of studies</h4> <p>All types of randomised controlled trials (RCTs), including cluster and cross‐over trials, were considered for inclusion. </p> </section> <section id="CD012005-sec-0046"> <h4 class="title">Types of participants</h4> <p>Children, adolescents and adults of all ages with a clinical diagnosis of Crohn's disease, ulcerative colitis (with or without a total colectomy), or any other form of IBD (e.g. indeterminate colitis or IBD unclassified) were considered for inclusion. Participants were included regardless of whether disease status was active or in remission. </p> </section> <section id="CD012005-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Any pharmacological and non‐pharmacological interventions designed to help alleviate fatigue in individuals with IBD were included. To be eligible for inclusion, an intervention must have a focus on fatigue explicitly stated in its aims, content, or as a primary or secondary outcome measure. </p> <p>The following comparisons were considered:</p> <p> <ul id="CD012005-list-0001"> <li> <p>Pharmacological versus non‐pharmacological;</p> </li> <li> <p>Pharmacological versus pharmacological (different drugs or same drugs with different doses and time intervals); </p> </li> <li> <p>Pharmacological versus usual or standard care;</p> </li> <li> <p>Non‐pharmacological versus usual or standard care;</p> </li> <li> <p>Non‐pharmacological versus non‐pharmacological (different non‐pharmacological interventions or same non‐pharmacological intervention with different formats); or </p> </li> <li> <p>Any of the above versus placebo.</p> </li> </ul> </p> <p>Interventions may be delivered in any form, for example, but not limited to face to face, telephone, the internet, or technology in the case of non‐pharmacological interventions. Interventions may be delivered individually or be group‐focused and occur in different settings such as a clinic or home environment. </p> </section> <section id="CD012005-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD012005-sec-0049"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for this review was fatigue. Therefore, eligible studies for inclusion must have fatigue or loss of energy measured as a primary or secondary outcome. Measures of fatigue are self‐reported as it is a subjective phenomenon and these instruments may be generic or disease‐specific. Examples of generic self‐reported measures include but are not limited to: the Fatigue Severity Scale (FSS) (<a href="./references#CD012005-bbs2-0127" title="KruppLB , LaRoccaNG , Muir‐NashJ , SteinbergAD . The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology1989;46(10):1121‐3. ">Krupp 1989</a>), Chalder Fatigue Scale (CFQ) (<a href="./references#CD012005-bbs2-0093" title="ChalderT , BerelowitzG , PawlikowskaT , WattsL , WesselyS , WrightD , et al. Development of a fatigue scale. Journal of Psychosomatic Research1993;37(2):147‐53. ">Chalder 1993</a>), Fatigue Impact Scale (FIS) (<a href="./references#CD012005-bbs2-0111" title="FiskJD , RitvoPG , RossL , HaaseDA , MarrieTJ , SchlechWF . Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clinical Infectious Diseases1994;18(Supplement 1):S79‐83. ">Fisk 1994</a>; <a href="./references#CD012005-bbs2-0112" title="FiskJD , DobleSE . Construction and validation of a fatigue impact scale for daily administration (D‐FIS). Quality of Life Research2002;11(3):263‐72. ">Fisk 2002</a>), Visual Analogue Scale of Fatigue (VAS‐F) (<a href="./references#CD012005-bbs2-0130" title="LeeKA , HicksG , Nino‐MurciaG . Validity and reliability of a scale to assess fatigue. Psychiatry Research1991;36(3):291‐8. ">Lee 1991</a>), Piper Fatigue Scale (PFS) (<a href="./references#CD012005-bbs2-0137" title="PiperBF , DibbleSL , DoddMJ , WeissMC , SlaughterRE , PaulSM . The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncology Nursing Forum1998;25(4):677‐84. ">Piper 1998</a>), Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT‐F) (<a href="./references#CD012005-bbs2-0153" title="YellenSB , CellaDF , WebsterK , BlendowskiC , KaplanE . Measuring fatigue and other anaemia‐related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management1997;13(2):63‐74. ">Yellen 1997</a>), Multidimensional Fatigue Inventory (MFI) (<a href="./references#CD012005-bbs2-0144" title="SmetsEM , GarssenB , CullA , DeHaesJC . Application of the multidimensional fatigue inventory (MFI‐20) in cancer patients receiving radiotherapy. British Journal of Cancer1996;73(2):241‐5. ">Smets 1996</a>), and the Multidimensional Assessment of Fatigue (MAF) (<a href="./references#CD012005-bbs2-0147" title="TackBB . Dimensions and Correlates of Fatigue in Older Adults with Rheumatoid Arthritis [PhD thesis]. San Francisco: University of California, 1991. ">Tack 1991</a>). An example of a disease‐specific measure includes the Inflammatory Bowel Disease‐Fatigue scale (IBD‐F) (<a href="./references#CD012005-bbs2-0100" title="Czuber‐DochanW , NortonC , BassettP , BerlinerS , BredinF , DarvellM , et al. Development and psychometric testing of inflammatory bowel disease fatigue (IBD‐F) patient self‐assessment scale. Journal of Crohn's and Colitis2014;8(11):1398‐406. ">Czuber‐Dochan 2014c</a>). </p> <p>In addition, studies that reported data on fatigue, loss of energy, vigour and vitality which was assessed as a single question or as a subscale of a questionnaire (e.g. the vitality subscale of the Short Form‐36 (SF‐36) or Inflammatory Bowel Disease Questionnaire (IBDQ) ( <a href="./references#CD012005-bbs2-0122" title="IrvineEJ . Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality‐of‐life instrument for adult patients with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition1999;28(4):S23‐7. ">Irvine 1999</a>; <a href="./references#CD012005-bbs2-0150" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. ">Ware 1992</a>) were included. Multidimensional characteristics of fatigue symptoms may be measured. For example, these characteristics may include intensity, severity, frequency, duration, distress or dimensions including physical fatigue, mental fatigue or general fatigue. </p> </section> <section id="CD012005-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included:</p> <p> <ul id="CD012005-list-0002"> <li> <p>Any measure of quality of life (e.g. validated generic or disease‐specific quality of life measures, such as the SF‐36 or IBDQ); and </p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <p>Adverse events included:</p> <p> <ul id="CD012005-list-0003"> <li> <p>The proportion of participants who experience any adverse event (i.e. an unfavourable outcome occurring during, but not necessarily caused by, the intervention); </p> </li> <li> <p>Serious adverse events (i.e. an adverse event that results in death, requires hospitalisation or a life‐threatening event, resulting in a persistent or significant disability); and </p> </li> <li> <p>Withdrawal due to adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012005-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012005-sec-0052"> <h4 class="title">Electronic searches</h4> <p>The databases Embase, MEDLINE, CINAHL, and PsycINFO were searched from inception to July 2018 and these searches were updated in October 2019. We also searched the Cochrane IBD Group Specialized Register and the Cochrane Central Register of Controlled trials (CENTRAL) for applicable RCTs. The search strategies were modified for each database. Search limits included humans and publication in English language only. The search strategies used the relevant database filters or the recommended Cochrane search string for the identification of RCTs (<a href="./references#CD012005-bbs2-0131" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). The search strategies for each database are reported in <a href="./appendices#CD012005-sec-0143">Appendix 1</a>, <a href="./appendices#CD012005-sec-0144">Appendix 2</a>, <a href="./appendices#CD012005-sec-0145">Appendix 3</a>, <a href="./appendices#CD012005-sec-0146">Appendix 4</a>, and <a href="./appendices#CD012005-sec-0147">Appendix 5</a>. One author (DF) liaised with the Cochrane IBD Group Trials Search Coordinator for the identification of potentially eligible studies. </p> </section> <section id="CD012005-sec-0053"> <h4 class="title">Searching other resources</h4> <p>To identify other relevant published, unpublished and ongoing trials we:</p> <p> <ul id="CD012005-list-0004"> <li> <p>Examined the reference lists of included studies and review articles for additional citations; </p> </li> <li> <p>Searched ongoing trials and research registers including the Current Controlled Trials register (www.controlled‐trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/en/), using the search terms 'fatigue' and 'inflammatory bowel disease' or 'ulcerative colitis' or 'Crohn’s disease'; </p> </li> <li> <p>Contacted trial authors to identify further published and unpublished trials and asked if they were willing to disclose their unpublished data; </p> </li> <li> <p>Searched published abstracts from conference proceedings, including the European Crohn’s and Colitis Organisation Congress, Digestive Disease Week and Advances in Inflammatory Bowel Diseases; and </p> </li> <li> <p>Searched relevant journals (Journal of Crohn's and Colitis; Inflammatory Bowel Diseases; Gastroenterology; Gastrointestinal Endoscopy). </p> </li> </ul> </p> </section> </section> <section id="CD012005-sec-0054"> <h3 class="title" id="CD012005-sec-0054">Data collection and analysis</h3> <section id="CD012005-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Initially, two review authors (DF and MA) independently screened and examined the eligibility of the titles and abstracts identified by the search based on the predetermined inclusion criteria described above. Full‐text papers were retrieved for all studies appearing to meet the inclusion criteria and were read independently by two review authors (DF and MA). Trials with a heterogeneous sample of disorders were included, only if relevant data from participants with IBD could be extracted. All trial authors were contacted regarding information that was unclear or missing in order to reach a decision about inclusion. In case of disagreement about the selection of a study, arbitration was sought from a third author with content expertise (CN) and a decision made by consensus. </p> </section> <section id="CD012005-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>For each included study, two review authors independently extracted and documented the relevant data using standardised data extraction forms. The lead author (DF) extracted data for all included studies (<a href="./appendices#CD012005-sec-0148">Appendix 6</a>). Second independent extraction of data from included studies was shared between three review authors (WCD or LPJJ or MA). All trial authors were contacted to provide additional (unpublished) relevant information. Any disagreements regarding inclusion or exclusion were resolved through discussion and by consultation with another author (CN) as necessary. </p> </section> <section id="CD012005-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For each study, the reviewers who extracted the data also independently assessed methodological quality using the Cochrane 'Risk of bias' tool (<a href="./references#CD012005-bbs2-0119" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We assessed trials for random sequence generation, allocation concealment, blinding (participants, personnel and outcome assessors), incomplete outcome data, outcome misclassification, selective outcome reporting and other potential sources of bias. We then made a judgement on each of these criteria relating to the risk of bias, of 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'. Judgement justification was provided in the <a href="./references#CD012005-sec-0156" title="">Characteristics of included studies</a> section of the review. When agreement was not achieved by the two paired review authors (DF and WCD or LPJJ or MA) through discussion, another review author (CN) provided consensus assessment. </p> </section> <section id="CD012005-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We used the Cochrane Collaboration’s Review Manager Software, RevMan 5, for all analyses. Outcomes were recorded both at the end of the intervention period and at the end of the follow‐up for the purpose of comparison between the intervention and control groups. These were the only time points at which outcomes were recorded in studies with multiple time points. We calculated the mean difference (MD) and the corresponding 95% confidence interval (CI) for continuous outcomes. We calculated the risk ratio (RR) and 95% CI for dichotomous outcomes. </p> </section> <section id="CD012005-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The level at which randomisation occurred was accounted for in the data analysis. We planned that the unit of analysis would be individuals for participants individually randomised to one of two groups. Where groups of individuals were randomised together to the same intervention (i.e. cluster‐randomised trials), we planned to contact the trial authors for further information if these group data were not reported. Where individuals underwent more than one intervention during the period of the study (i.e. cross‐over trial), we planned to only include the first part of the study (i.e. before the cross‐over) to avoid potential carry‐over effects. For multi‐arm pharmacological trials with a single placebo group and two treatment dose groups, we planned to split the placebo group in half to avoid a unit of analysis error (<a href="./references#CD012005-bbs2-0120" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We did not find any available cluster‐randomised or cross‐over studies. However, we did find study designs where multiple treatment attempts were used, therefore, we selected the dose group that reflected clinical practice as the comparison for all continuous variables, as a mean and standard deviation for each placebo comparator was not possible. </p> </section> <section id="CD012005-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>Data were analysed on an intention‐to‐treat basis. Where data were missing, we contacted the trial authors and requested the missing data. The trial authors who replied to our additional information request are detailed in the '<a href="#CD012005-sec-0140">Acknowledgements</a>' section. If this information was unattainable, we planned to undertake an available case analysis by analysing only the available data (i.e. ignoring the missing data). If change scores were not available and the mean change could be calculated, we planned to impute standard deviations from baseline data using methods recommended in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012005-bbs2-0120" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). If the number of patients randomised to each group and the number of dropouts were known, we planned to calculate a worst case intention‐to‐treat (ITT) analysis, where by all dropouts were assumed to be treatment failures. </p> </section> <section id="CD012005-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>The studies were assessed for clinical homogeneity with regards to participants, interventions and outcomes. We planned to assess statistical heterogeneity in terms of the difference in the effects of interventions, by firstly visually inspecting the forest plots and secondly using statistical tests of variation (Chi² and I² statistics). We planned to investigate heterogeneity by visually inspecting the forest plots to identify outliers. If outliers were identified, we would conduct sensitivity analysis to explore potential explanations for the heterogeneity. For the Chi² test, a P value of less than 0.1 would be considered statistically significant. We planned to use the I² statistic to quantify heterogeneity (I² 0% ‐ 40%: low heterogeneity; I² 30% – 60%: moderate heterogeneity; 50% ‐ 90%: substantial heterogeneity; 75 – 100%: considerable heterogeneity) (<a href="./references#CD012005-bbs2-0120" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). However, the size of the I² would be interpreted in light of the size and direction of effects, as well as the strength of evidence for heterogeneity (e.g. P value from Chi² test). If heterogeneity was suspected, the possibility of utilising a random‐effects model of meta‐analysis would be considered as recommended in Chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD012005-bbs2-0105" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane–handbook.org.. ">Deek 2011</a>). We pooled statistically homogeneous studies (I² &lt; 50%) using a fixed‐effect model. </p> </section> <section id="CD012005-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>All studies were assessed for reporting bias. We assessed selective reporting by comparing outcomes that were prespecified in study protocols to those reported in study manuscripts. If protocols were not available for the included studies, we assessed reporting bias by comparing the outcomes specified in the methods section of the manuscript to those reported in the results section. If there were more than 10 included studies in a pooled analysis, we planned to investigate publication bias by constructing funnel plots (<a href="./references#CD012005-bbs2-0145" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> <section id="CD012005-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We combined data from individual studies when the interventions, participant groups and outcomes were sufficiently similar, which was determined by consensus. When pooling studies was not possible, we narratively summarised the results of individual studies. For continuous outcomes, we calculated the pooled mean difference (MD) and corresponding 95% CI. For continuous outcomes that utilised difference scales to measure the same underlying construct, we planned to calculate the standardised mean difference (SMD) and corresponding 95% CI. For dichotomous outcomes, we planned to calculate the pooled risk ratio (RR) and 95% CI. </p> </section> <section id="CD012005-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient power and data were available, we planned to perform subgroup analyses to investigate possible reasons for variations in fatigue results across trials for the following subsets: disease type (Crohn’s disease, ulcerative colitis); disease activity (active disease, inactive disease), sex (male, female); age groups (child, adolescents, adults, elderly (aged 65 years and old)), comorbidities, and intervention type (pharmacological, non‐pharmacological). </p> </section> <section id="CD012005-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis, where appropriate, to explore the effects of risk of bias on fatigue. For example, studies identified as having high risk of bias would be excluded from the pooled analysis to see if the effect estimate changed in a substantive way. However, due to insufficient data, sensitivity analysis was deemed not appropriate in this review. </p> <section id="CD012005-sec-0066"> <h5 class="title">Summary of findings and assessment of the certainty of the evidence</h5> <p>We used the GRADE criteria (risk of bias, inconsistency, imprecision, indirectness and publication bias) to assess the overall quality of evidence for the prespecified primary and secondary outcomes (<a href="./references#CD012005-bbs2-0142" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>; <a href="./references#CD012005-bbs2-0143" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>). Using this approach, outcome data were rated high, moderate, low or very low certainty. All decisions to downgrade the quality of the evidence were explained using footnotes. </p> <p>Using the GRADEpro software, a 'Summary of findings' table was created for the following outcomes: </p> <p> <ul id="CD012005-list-0005"> <li> <p>Fatigue;</p> </li> <li> <p>Quality of life;</p> </li> <li> <p>Adverse events:</p> </li> <li> <p>Serious adverse events; and</p> </li> <li> <p>Withdrawal due to adverse events.</p> </li> </ul> </p> <p>Comparisons where the primary intention of the intervention was management of fatigue were prioritised for presentation in summary of findings tables. Other comparisons, where the management of fatigue was not the primary intention of the intervention with fatigue being assessed as a secondary outcome, were presented as additional tables. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012005-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012005-sec-0067"></div> <section id="CD012005-sec-0068"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012005-sec-0156" title="">Characteristics of included studies</a> and <a href="./references#CD012005-sec-0157" title="">Characteristics of excluded studies</a>. </p> <section id="CD012005-sec-0069"> <h4 class="title">Results of the search</h4> <p>The electronic search identified a total of 3183 citations (<a href="#CD012005-fig-0001">Figure 1</a>) of which 3055 were excluded based on titles and abstracts alone. The search of conference abstracts, relevant journals, reference lists, ongoing trials and research registers, and contact with trial authors yielded 18 further potentially eligible citations. The full texts of 91 reports were examined in detail. A total of 34 citations were excluded, mostly as fatigue outcome data were not assessed or reported (n = 24), not an RCT design (n = 7), or data from IBD participants was not presented separately (n = 3). A total of fourteen trials were identified as meeting the inclusion criteria of this review (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Furthermore, 27 ongoing trials were identified as eligible and will be included in future updates of this review (<a href="./references#CD012005-bbs2-0054" title="ACTRN12617000586314P . A prospective randomized multicentre study to evaluate the effect of intravenous iron infusion compared to oral iron supplementation on the quality of life in inflammatory bowel disease with non‐anaemia hypoferritinanaemia. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372758 (first received 17 April 2017). ">ACTN12617000586314P</a>; <a href="./references#CD012005-bbs2-0056" title="EudraCT Number:2008‐004277‐17 . The effectiveness and tolerability of GlobiFer (haem iron) tablets compared to ferrous sulphate tablets in inflammatory bowel disease: a randomised‐controlled trial. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐004277‐17/GB (first received 15 March 2010). ">EudraCT Number: 2008‐004277‐17</a>; <a href="./references#CD012005-bbs2-0057" title="EudraCT Number:2011‐002122‐43 . Iron therapy in IBD patients with normal levels of haemoglobin and chronic fatigue. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2011‐002122‐43 (first received). ">EudraCT Number: 2011‐002122‐43</a>; <a href="./references#CD012005-bbs2-0058" title="EUCTR2012‐005644‐26‐BE . Administration of intravenous ferric carboxymaltose to children with IBD. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=EUCTR2012‐005644‐26‐BE (first received ). ">EudraCT Number: 2012‐005644‐26</a>; <a href="./references#CD012005-bbs2-0060" title="NCT02193750 . Assessing the tolerability of oligosaccharide supplementation in patients with Crohn's disease: A randomized, controlled trial. https://clinicaltrials.gov/ct2/show/NCT02193750 (first received 18 July 2014). ">NCT02193750</a>; <a href="./references#CD012005-bbs2-0061" title="NCT02208310 . A randomised controlled trial of high‐dose vitamin D in Crohn's disease. https://clinicaltrials.gov/ct2/show/NCT02208310 (first received 5 August 2014). ">NCT02208310</a>; <a href="./references#CD012005-bbs2-0062" title="NCT02517151 . Effects of iron therapy in patients with chronic fatigue and IBD. https://clinicaltrials.gov/ct2/show/NCT02517151 (first received 6 August 2015). ">NCT02517151</a>; <a href="./references#CD012005-bbs2-0063" title="NCT02704624 . The impact of serum vitamin D and calcium levels on the body composition, bone mineral density, muscle strength, exercise tolerance, fatigue and inflammatory activity in patients with Crohn's disease: a randomized controlled trial. https://ClinicalTrials.gov/show/NCT02704624 (first received 10 March 2016). ">NCT02704624</a>; <a href="./references#CD012005-bbs2-0064" title="NCT02707068 . Quality Of LIfe Tool for IBD (QOLITI): pilot testing of a self‐administered intervention to target psychological distress in inflammatory bowel disease. https://clinicaltrials.gov/show/NCT02707068 (first received 14 March 2016). ">NCT02707068</a>; <a href="./references#CD012005-bbs2-0065" title="NCT02772965 . A randomized, double‐blind, placebo‐controlled, multi‐center pragmatic clinical trial to evaluate the effectiveness of low dose oral methotrexate in patients with pediatric Crohn's disease initiating anti‐TNF therapy. https://clinicaltrials.gov/ct2/show/NCT02772965 (first received 16 May 2016). ">NCT02772965</a>; <a href="./references#CD012005-bbs2-0066" title="NCT02849717 . Pre‐habilitation exercise intervention for patients scheduled for colorectal surgical resection. clinicaltrials.gov/ct2/show/NCT02849717 (first received 29 July 2016). ">NCT02849717</a>; <a href="./references#CD012005-bbs2-0067" title="NCT02861053 . Inflammatory Bowel Disease: Could a regular physical activity reduce patients fatigue?. https://clinicaltrials.gov/ct2/show/NCT02861053 (first received 10 August 2016). ">NCT02861053</a>; <a href="./references#CD012005-bbs2-0068" title="NCT02891226 . A phase 2, multicenter, randomized, parallel‐arm, placebo‐controlled study of LY3074828 in subjects with active Crohn's Disease (SERENITY). https://clinicaltrials.gov/ct2/show/NCT02891226 (first received 7 September 2016). ">NCT02891226</a>; <a href="./references#CD012005-bbs2-0069" title="NCT02963246 . Effects of a mindfulness therapy intervention for individuals with inflammatory bowel disease: a randomized controlled trial. https://clinicaltrials.gov/ct2/show/NCT02963246 (first received 15 November 2016). ">NCT02963246</a>; <a href="./references#CD012005-bbs2-0070" title="NCT03104413 . A multicenter, randomized, double‐blind, placebo‐controlled induction study to assess the efficacy and safety of Risankizumab in subjects with moderately to severely active Crohn's disease who failed prior biologic treatment. https://clinicaltrials.gov/show/NCT03104413 (first received 7 April 2017). ">NCT03104413</a>; <a href="./references#CD012005-bbs2-0071" title="NCT03105102 . A multicenter, randomized, double‐blind, placebo controlled 52‐week maintenance and an open‐label extension study of the efficacy and safety of Risankizumab in subjects with Crohn's disease who responded to induction treatment in M16‐006 or M15‐991; or completed M15‐989. ClinicalTrials.gov/show/NCT03105102 (first received 7 April 2017). ">NCT03105102</a>; <a href="./references#CD012005-bbs2-0072" title="NCT03105128 . A multicenter, randomized, double‐blind, placebo controlled induction study of the efficacy and safety of Risankizumab in subjects with moderately to severely active Crohn's disease. ClinicalTrials.gov/show/NCT03105128 (first received 7 April 2017). ">NCT03105128</a>; <a href="./references#CD012005-bbs2-0073" title="NCT03107793 . Study of treat to target versus routine care maintenance strategies in Crohn's disease patients treated with Ustekinumab. clinicaltrials.gov/ct2/show/NCT03107793 (first received 11 April 2017). ">NCT03107793</a>; <a href="./references#CD012005-bbs2-0074" title="NCT03162575 . The possible beneficial effects of mindfulness‐based cognitive therapy (MBCT) in fatigued adult patients with Inflammatory Bowel Disease (IBD). clinicaltrials.gov/ct2/show/NCT03162575 (first received 22 May 2017). ">NCT03162575</a>; <a href="./references#CD012005-bbs2-0075" title="NCT03266484 . Effect of dietary therapy with a probiotic mixture on the gut microbiome and fatigue symptoms in patients with quiescent inflammatory bowel disease ‐ A clinical trial. clinicaltrials.gov/ct2/show/NCT03266484 (first received 30 August 2017). ">NCT03266484</a>; <a href="./references#CD012005-bbs2-0076" title="NCT03345823 . A multicenter, randomized, double‐blind, placebo‐controlled maintenance and long‐term extension study of the efficacy and safety of Upadacitinib (ABT‐494) in subjects with Crohn's disease who completed the studies M14‐431 or M14‐433. clinicaltrials.gov/ct2/show/NCT03345823 (first received 17 November 2017). ">NCT03345823</a>; <a href="./references#CD012005-bbs2-0077" title="NCT03345836 . A multicenter, randomized, double‐blind, placebo‐controlled induction study of the efficacy and safety of Upadacitinib (ABT‐494) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to biologic therapy. clinicaltrials.gov/ct2/show/NCT03345836 (first received 17 November 2017). ">NCT03345836</a>; <a href="./references#CD012005-bbs2-0078" title="NCT03345849 . A multicenter, randomized, double‐blind, placebo‐controlled induction study of the efficacy and safety of Upadacitinib (ABT‐494) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are Intolerant to conventional and/or biologic therapies. clinicaltrials.gov/ct2/show/NCT03345849 (first received 17 November 2017). ">NCT03345849</a>; <a href="./references#CD012005-bbs2-0079" title="NCT03398135 . A multicenter, randomized, double‐blind, placebo controlled 52‐week maintenance and an open‐label extension study of the efficacy and safety of Risankizumab in subjects with ulcerative colitis who responded to induction treatment in M16‐067 or M16‐065. clinicaltrials.gov/ct2/show/NCT03398135 (first received 12 January 2018). ">NCT03398135</a>; <a href="./references#CD012005-bbs2-0080" title="NCT03398148 . A multicenter, randomized, double‐blind, placebo controlled induction study to evaluate the efficacy and safety of Risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapy. clinicaltrials.gov/ct2/show/NCT03398148 (first received 12 January 2018). ">NCT03398148</a>; <a href="./references#CD012005-bbs2-0081" title="NCT03456752 . The Impact of perioperative dexamethasone on postoperative outcome in inflammatory bowel diseases. clinicaltrials.gov/ct2/show/NCT03456752 (first received 7 March 2018). ">NCT03456752</a>; <a href="./references#CD012005-bbs2-0082" title="NCT03466411 . A phase 2/3, randomized, double‐blind, placebo‐ and active‐controlled, parallel‐group, multicenter protocol to evaluate the efficacy and safety of Guselkumab in participants with moderately to severely active Crohn's disease. clinicaltrials.gov/ct2/show/NCT03466411 (first received 15 March 2018). ">NCT03466411</a>) (<a href="./references#CD012005-sec-0159" title="">Characteristics of ongoing studies</a>). </p> <div class="figure" id="CD012005-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012005-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>The electronic search was re‐run in October 2019, which identified an additional 337 citations (<a href="#CD012005-fig-0001">Figure 1</a>). Five potentially relevant studies (<a href="./references#CD012005-bbs2-0049" title="GhoshS , AberraF , CrossR , ZhouW , ChenN , LeeWJ , et al. Effect of upadacitinib on patient‐reported symptoms by the new ulcerative colitis symptoms questionnaire (UC‐SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U‐ACHIEVE. Journal of Crohn's and Colitis2019;13:S247‐S248. NCT02819635 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety and efficacy of upadacitinib (ABT‐494) for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. clinicaltrials.gov/ct2/show/NCT02819635 (first received 30 June 2016). ">Ghosh 2019</a>; <a href="./references#CD012005-bbs2-0050" title="LouisE , SandbornWJ , D'HaensG , BaertF , KalabicJ , WallaceK , et al. Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn's disease: phase 2 trial results. Journal of Crohn's and Colitis2019;13:S291‐S292. NCT02031276 . A phase II, multicenter, randomized, double‐blind, multiple dose, placebo‐controlled, parallel‐group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066/ABBV‐066 (risankizumab), and IL‐23 p19 antagonist monoclonal antibody in patients with ,moderately to severely active Crohn's disease who are naïve to, or were previously treated with, anti‐TNF therapy. clinicaltrials.gov/ct2/show/NCT02031276 (first received 9 January 2014). ">Louis 2019</a>; <a href="./references#CD012005-bbs2-0051" title="NCT02709434 . The efficacy of a structured psychoeducational inflammatory bowel disease group on the control of fatigue in an adult outpatient setting for patients with objectively quiescent disease. ClinicalTrials.gov/show/NCT02709434 (first received 16 March 2016). O'ConnorA , RatnakumaranR , WarrenL , PullenD , ErringtonA , GracieDJ , et al. Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. Therapeutic Advances in Chronic Disease2019;10:1‐12. [DOI: 10.1177/2040622319838439] ">O' Connor 2019</a>; <a href="./references#CD012005-bbs2-0052" title="SandsBE , PiresA , GasinkC , LalimanV , HanC , FeaganBG . Post hoc analysis of the impact of ustekinumab treatment on specific items of the Inflammatory Bowel Disease Questionnaire in the Uniti‐1 &amp; 2 programs. Gastroenterology2018;154:S‐811. ">Sands 2018</a>; <a href="./references#CD012005-bbs2-0053" title="ISRCTN13021107 . A randomised controlled trial investigating the feasibility and acceptability of high‐intensity interval training and moderate‐intensity continuous training in adults with inactive or mildly active Crohn’s disease. www.isrctn.com/ISRCTN13021107 (first received 2 December 2015). TewGA , LeightonD , CarpenterR , AndersonS , LangmeadL , RamageJ , et al. High‐intensity interval training and moderate‐intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial. BMC Gastroenterology2019;19(1):19. ">Tew 2019</a>) and three ongoing trials (<a href="./references#CD012005-bbs2-0055" title="ACTRN12619000150145 . Influence of extra virgin olive oil intake on disease activity and gut microbiota profile of community dwelling adults with ulcerative colitis in comparison to healthy subjects. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375208 (first received 24 January 2019). ">ACTRN12619000150145</a>; <a href="./references#CD012005-bbs2-0059" title="ISRCTN11470370 . Effects of a 6‐month practical resistance training programme on muscle function and bone mineral density in adults with inactive or mildly active Crohn’s disease: Study protocol for a randomised controlled trial. http://www.isrctn.com/ISRCTN11470370 (first received 11 December 2017). ">ISRCTN11470370</a>; <a href="./references#CD012005-bbs2-0083" title="NCT03574948 . Multicentric, double‐blind, placebo controlled clinical trial with 5‐hydroxytryptophan (5‐HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores. clinicaltrials.gov/ct2/show/NCT03574948 (first received 2 July 2018). ">NCT03574948</a>) were identified. Additional information is needed from the study authors and these studies will be assessed for inclusion at the next update (<a href="./references#CD012005-sec-0158" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD012005-sec-0159" title="">Characteristics of ongoing studies</a>) </p> </section> <section id="CD012005-sec-0070"> <h4 class="title">Included studies</h4> <p>Fourteen trials published in peer‐reviewed journals (28 citations) were included in this review. Multiple records for ten of the trials were identified: four trials were reported in conference proceeding abstracts (and published in journals) (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>) and six trials were reported in journal articles and conference proceeding abstracts (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). The primary reference for four trials did not report fatigue (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), however secondary publications reported the outcome (Loftus 2008; Panaccione 2018; Rubin 2009; Rubin 2018). Therefore, for the purpose of this review, the trials were included as eligible studies and the primary publication (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) was used as the study identifier. In one trial (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>), results for all randomised participants were presented in a conference proceedings abstract (Rubin 2009) and results from a subset of participants (participants who responded [achieved clinically meaningful change in disease activity by week 4] to open‐label adalimumab induction therapy) were presented in a full‐text paper (Loftus 2008). For the purpose of data synthesis, the results from all randomised participants and randomised responders were presented separately in this review, as the sample sizes and fatigue data differed between the datasets. Another secondary publication (Rubin 2018) presented fatigue subcomponent data from both the GEMINI I and II trials in a conference proceedings abstract, therefore, these two trials were presented as eligible studies in this review (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). A total of five trials were reported in insufficient detail to allow for inclusion in the analysis (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), however we are currently awaiting additional information from one trial (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>). </p> <section id="CD012005-sec-0071"> <h5 class="title">Type of studies</h5> <p>All studies used standard therapy as a comparator. In three studies, a three‐arm design was used, with two studies including two intervention arms and a control group (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>) and one study including an intervention and sham arm and a control group (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). In one study, a four‐arm design was used (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). </p> <p>Six studies were double‐blinded (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), with the remaining studies single‐blinded (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) or unblinded (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Four studies used open allocation (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), three used an interactive voice response system (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>) and two studies used sealed opaque envelopes (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). One study used a combination of open allocation and sequentially named drug containers of identical appearance (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Four studies (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) did not present information on group allocation. </p> <p>The follow‐up time ranged from 21 days (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) to 56 weeks (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). Only two studies had a follow‐up period longer than 12 months (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). </p> </section> <section id="CD012005-sec-0072"> <h5 class="title">Populations</h5> <p>All studies were conducted on adults. Sample size ranged from 27 participants (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>) to 1115 participants (<a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). Most sample sizes were small (&lt; 100 participants) (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Settings varied from single (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) to multicentred studies (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). It is unclear if one study (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>) was a single or multicentred study. The multicentred studies ranged from two centres (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>) to 285 centres (<a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). Most studies recruited participants from hospital‐based settings, specifically inflammatory bowel disease clinics (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), with the specific location of recruitment unclear for some studies, although it appeared to be hospital‐based (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Most studies were conducted in European countries (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a><a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), with four trials being conducted worldwide (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). </p> <p>Some studies sampled those with a diagnosis of Crohn's disease (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), with two studies focused specifically on ulcerative colitis only (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>). The remaining studies recruited individuals with Crohn's disease and ulcerative colitis (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) or inflammatory bowel disease (Crohn's disease, ulcerative colitis and unclassified) (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). In all studies, results were presented as an overall group rather than by disease type. </p> <p>Disease status or activity was defined as an inclusion criterion in all studies, except one (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>). Some studies recruited participants in remission only (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Other studies recruited individuals with mixed disease activity, including remission or mild‐ to‐moderate disease (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>), mild‐to‐moderately active disease (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) and moderate‐to‐severely active disease (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). For Crohn's disease, the Crohn's Disease Activity Index (CDAI) was most commonly used, with remission defined as a CDAI score &lt; 150 (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), mild‐to‐moderately active disease defined as a CDAI score &lt; 220 (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>) and moderate‐to‐severely active disease defined as a CDAI score 220 to 450 (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). The Harvey Bradshaw Index (HBI) (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) and the short CDAI (<a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) were also used to characterise disease activity for Crohn's disease populations. For ulcerative colitis, the Simple Clinical Colitis Activity Index (SSCAI) (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>), the Clinical Activity Index (CAI) (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and the Mayo score (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>) were used. Although there was consistency in defining disease activity in Crohn's disease, disparity existed in the cut‐off points for the ulcerative colitis disease activity indices. For example, remission was defined as SSCAI score &lt; 4 (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>) and also as a score &lt; 3 (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Remission was also defined in a study as CAI score &lt; 10 (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), however, a CAI score ≥ 3 indicated a mild‐to‐moderate active disease (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>). Some studies (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) also used c‐reactive protein (CRP) levels as a measure of disease activity, however, the studies differed in terms of the cut‐off used to define remission [ranging from &lt;5 mg/dL (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) to &lt; 10mg/dL (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>)] and moderately‐to‐severely active disease [ranging from &gt; 2.87 mg/L (<a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) to ≥ 5 mg/L (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>). Endoscopy disease activity scores (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) and faecal calprotectin (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>) were also used to evaluate disease activity of eligible participants. </p> <p>Studies used different inclusion criteria, such as a history of TNF‐antagonist treatment (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) or drug treatments (sulfasalazine or 5ASA) (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), iron deficiency anaemia (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>) and fatigue severity (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). </p> <p>The loss to follow‐up ranged from 0% (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>) to 34% (<a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), although most studies had less than 25% loss to follow‐up (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Information regarding loss to follow‐up was not available for two studies (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). </p> </section> <section id="CD012005-sec-0073"> <h5 class="title">Interventions</h5> <p>Most studies measured fatigue as a secondary outcome, with only four trials specifically designed for managing fatigue (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Mostly trials were pharmacological (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), with four studies being non‐pharmacological (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). One study used a multi‐interventional approach of both pharmacological and non‐pharmacological interventions (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). The pharmacological interventions included adalimumab (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>), vedolizumab (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), iron therapies (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>), and supplements, such as agaricus blazei murill‐based mushroom extract (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), omega 3 (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) and vitamin D3 (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). One trial used a combination customised pharmacological therapy, including prednisone, adalimumab and azathioprine (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>). The non‐pharmacological interventions included cognitive behavioural therapy with therapist support (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>), electroacupuncture (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>), stress management (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), solution‐focused therapy (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and physical activity advice (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). </p> <p>Most of the pharmacological interventions were oral therapies administered daily (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>) or twice daily (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), although five studies involved intravenous (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) or subcutaneous injection treatments (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>), administered either weekly (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>), every other week (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), as two stat doses (three to eight days apart) (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>) or every four or eight weeks (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). The duration of administration of regularly administered pharmacological interventions ranged from 21 days (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) to 58 weeks (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). The duration of the pharmacological interventions for three studies was 12 weeks (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). </p> <p>The non‐pharmacological interventions ranged from face‐to‐face or telephone/Skype individuals sessions (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), group sessions (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) to self‐directed sessions using a written guide and audiotape (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). The intensity of the interventions varied from a one‐off 15‐minute consultation on physical activity (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) to nine electroacupuncture sessions over an eight week period (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). These non‐pharmacological interventions were delivered in the hospital (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) or in the participants' homes (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). </p> </section> <section id="CD012005-sec-0074"> <h5 class="title">Outcomes</h5> <section id="CD012005-sec-0075"> <h6 class="title">Fatigue</h6> <p>Fatigue was assessed in studies either using a generic or disease‐specific fatigue scale, as a subscale of a broader questionnaire or as a single‐item question. Predominantly, fatigue was assessed using a single scale (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), the remaining four studies used two (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) or three different fatigue scales (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Fatigue was most commonly assessed using the generic fatigue scale, the Functional Assessment of Chronic Illness Therapy ‐ Fatigue (FACIT‐F) scale, in five studies (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Other generic scales of fatigue, included the Multidimensional Fatigue Inventory (MFI) (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>), the Fatigue Questionnaire (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), the Checklist of Individual Strength (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and the Fatigue Severity Scale (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Six studies presented fatigue data from a single‐item question (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), or as a subscale or subcomponent of quality of life questionnaires (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). Only two studies assessed fatigue using a disease‐specific fatigue measure, namely the IBD‐Fatigue scale (IBD‐F) (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Summary data for fatigue were not available in five studies (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), therefore, although eligible studies, the findings could not be included in the analysis of this review. </p> </section> <section id="CD012005-sec-0076"> <h6 class="title">Quality of life</h6> <p>The secondary outcome of this review, quality of life, was assessed in twelve of the fourteen studies (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Four studies measured the outcome using both a generic and disease‐specific quality of life questionnaire (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Six studies (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) used a disease‐specific measure of quality of life and two studies used a generic measure (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). The most commonly used generic quality of life questionnaire was the Short Form‐36 (SF‐36) (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), however, the EuroQual (EQ‐5D) was also used (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). The most common disease‐specific quality of life questionnaire used was the Inflammatory Bowel Disease Questionnaire (IBDQ) (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), the UK IBDQ (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>) and the IBDQ‐9 (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). </p> <p>Of the twelve studies, five studies presented total quality of life scores (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Two studies reported not analysing total quality of life scores (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), whereas other studies did not publish summary data for quality of life (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). </p> </section> <section id="CD012005-sec-0077"> <h6 class="title">Adverse events</h6> <p>Adverse (AEs) were assessed in ten of the fourteen eligible studies (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). Three non‐pharmacological trials did not assess adverse events (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), whereas most of the pharmacological and multimodular trials reported adverse events. It is unclear if one pharmacological study assessed adverse events as it was not presented in the report and the information remains unavailable (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). The assessment of adverse events varied considerably across the studies, with methods including the MedDRA system organ class and preferred terms (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), medication diaries (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) and interviews (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) being employed. Specific predefined adverse events were reported in one trial (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>). </p> </section> <section id="CD012005-sec-0078"> <h6 class="title">Other outcomes</h6> <p>Due to the diverse nature of the eligible trials included in this review, other outcomes were also assessed in the trials. For example, the iron therapy interventions assessed Hgb concentration and transferrin saturation (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>), along with serum ferritin concentration (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>), whereas the physical activity advice intervention assessed physical activity and body composition (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Disease activity was assessed in a number of studies using established measures (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), and faecal calprotectin levels (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Many of the pharmacological trials assessed disease activity response and remission as primary outcomes of interest (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). Some of the studies assessed a number of blood tests, such as inflammatory levels (CRP) (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), full blood count (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>), ethylenediamine tetraacetic acid (EDTA) (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), and serum 25(OH)D (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). Psychological outcomes, such as depression (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and anxiety (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), and self‐reported outcomes including sleepiness (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>), sleep quality (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and illness perception (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>) were other outcomes assessed. Of these outcomes, only those related to fatigue, quality of life and adverse events were extracted for this review. </p> </section> </section> </section> <section id="CD012005-sec-0079"> <h4 class="title">Excluded studies</h4> <p>Of the 91 reports reviewed, 34 citations were excluded. The majority (n = 24) were excluded as fatigue was not assessed as a primary or secondary outcome in the trial. These trials assessed quality of life using generic or disease‐specific measures, so potentially they were eligible to be included. However, as the subscale data on fatigue, loss of energy, vitality or vigour were not reported, these were excluded (<a href="./references#CD012005-bbs2-0015" title="BoyeB , LundinKE , JantschekG , LegangerS , MoklebyK , TangenT , et al. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomised controlled trial. Inflammatory Bowel diseases2011;17(9):1863‐73. ">Boye 2011</a>; <a href="./references#CD012005-bbs2-0016" title="ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ">Colombel 2010</a>; <a href="./references#CD012005-bbs2-0017" title="CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomised controlled trial. Gastroenterology2013;145(4):758‐65. ">Cosnes 2013</a>; <a href="./references#CD012005-bbs2-0018" title="DewintP , HansenBE , VerheyE , OldenburgB , HommesDW , PierikM , et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double‐blind, placebo controlled trial (ADAFI). Gut2014;63(2):292‐9. ">Dewint 2014</a>; <a href="./references#CD012005-bbs2-0019" title="FeaganBG , YanS , BalaM , BaoW , LichtensteinGR . The effects of infliximab maintenance therapy on health‐related quality of life. American Journal of Gastroenterology2003;98(10):2232‐8. ">Feagan 2003</a>; <a href="./references#CD012005-bbs2-0022" title="LeiperK , WoolnerJ , MullanMMC , ParkerT , Van derVlietM , FearS , et al. A randomised controlled trail of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut2001;49(6):790‐4. ">Leiper 2001</a>; <a href="./references#CD012005-bbs2-0023" title="LichtensteinGR , BalaM , ChenglongH , DeWoodyK , SchaibleT . Infliximab improves quality of life in patients with Crohn’s disease. Inflammatory Bowel Diseases2002;8(4):237‐43. ">Lichtenstein 2002</a>; <a href="./references#CD012005-bbs2-0025" title="LoftusEV , ColombelJF , FeaganBG , VermeireS , SandbornWJ , SandsBE , et al. Long‐term efficacy of vedolizumab for ulcerative colitis. Journal of Crohn's and Colitis2017;11(4):400‐11. ">Loftus 2017</a>; <a href="./references#CD012005-bbs2-0026" title="MaragkoudakiM , ChouliarasG , PapadopoulouA , ChristakiM . Feasibility and effectiveness of a psycho‐educational program in adolescents with Inflammatory Bowel Disease (IBD). Journal of Pediatric Gastroenterology and Nutrition2016;61:363. ">Maragkoudaki 2016</a>; <a href="./references#CD012005-bbs2-0027" title="Mikocka‐WalusA , HughesPA , BamptonP , GordonA , CampanielloMA , MavrangelosC , et al. Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn’s disease: a pilot randomized placebo‐controlled trial. Journal of Crohn's and Colitis2017;11(4):509‐14. ">Mikocka‐Walus 2017</a>; <a href="./references#CD012005-bbs2-0032" title="ParamsothyS , KammMA , KaakoushNO , WalshAJ , Van denBogaerdeJ , SamuelD , et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo‐controlled trial. Lancet2017;389(10075):1218‐28. ">Paramsothy 2017</a>; <a href="./references#CD012005-bbs2-0033" title="Pena RossiC , HanauerSB , TomasevicR , HunterJO , ShafranI , GraffnerH . Interferon beta‐1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose‐finding study. BMC Gastroenterology2009;9:22. ">Pena Rossi 2009</a>; <a href="./references#CD012005-bbs2-0035" title="ReuschA , WeilandR , GerlichC , DregerK , DerraC , MainosD , et al. Self‐management education for rehabilitation inpatients suffering from inflammatory bowel disease: a cluster randomized controlled trial. Health Education Research2016;31(6):782‐91. ">Reusch 2016</a>; <a href="./references#CD012005-bbs2-0036" title="SandsBE , SandbornWJ , FeaganB , LöfbergR , HibiT , WangT , et al. A randomised, double‐blind, sham‐controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastreoenterology2008;135(2):400‐9. ">Sands 2008</a>; <a href="./references#CD012005-bbs2-0037" title="SandsBE , KatzS , WolfDC , FeaganBG , WangT , GustofsonL‐M , et al. A randomised, double‐blind, sham‐controlled study of granulocyte apheresis for moderate to severe Crohn's disease. Gut2013;62(9):1288‐94. ">Sands 2013</a>; <a href="./references#CD012005-bbs2-0038" title="SchmidtC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , HowaldtS , et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a phase 3 study. Alimentary Pharmacology and Therapeutics2016;44:259‐70. ">Schmidt 2016</a>; <a href="./references#CD012005-bbs2-0040" title="SchreiberS , KeshavarzianA , IsaacsKL , SchollenbergerJ , GuzmanJP , OrlandiC , et al. A randomised, placebo‐controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology2007;132(1):76‐86. ">Schreiber 2007</a>; <a href="./references#CD012005-bbs2-0041" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomised placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2011</a>; <a href="./references#CD012005-bbs2-0042" title="SmithJP , FieldD , BingamanS , EvansR , MaugerD . Safety and tolerability of low dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. Journal of Clinical Gastroenterology2013;47(4):339‐45. ">Smith 2013</a>; <a href="./references#CD012005-bbs2-0043" title="SteinhartAH , FeaganBG , WongCJ , VandervoortM , MikolainisS , CroitoruK , et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomised controlled trial. Gastroenterology2002;123(1):33‐40. ">Steinhart 2002</a>; <a href="./references#CD012005-bbs2-0045" title="TarganSR , FeaganBG , FedorakRN , LashnerBA , PanaccioneR , PresentDH , et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology2007;132(5):1672‐83. ">Targan 2007</a>; <a href="./references#CD012005-bbs2-0046" title="ValentineJF , FedorakRN , FeaganB , FredlundP , SchmittR , NiP , et al. Steriod‐sparing properties of sargramostim in patients with corticosteroid‐dependent Crohn's disease: a randomised, double‐blind, placebo‐controlled, phase 2 study. Gut2009;58(10):1354‐62. ">Valentine 2009</a>; <a href="./references#CD012005-bbs2-0047" title="VanAsscheG , VermeireS , BalletV , GabrielsF , NomanM , D'HaensG , et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut2012;61(2):229‐34. ">Van Assche 2012</a>; <a href="./references#CD012005-bbs2-0048" title="VermeireS , LoftusEV , ColombelJF , FeaganBG , SandbornWJ , SandsBE . Long‐term efficacy of vedolizumab for Crohn’s Disease. Journal of Crohn's and Colitis2017;11(4):412‐24. ">Vermeire 2017</a>). Seven studies were excluded as a randomised controlled trial design was not employed (<a href="./references#CD012005-bbs2-0024" title="LoftusE , ColombelJ , PollackP , MajethiaS , ChenN . Adalimumab treatment associated with rapid and significant improvement in health‐related quality of life in patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1). ">Loftus 2009</a>; <a href="./references#CD012005-bbs2-0028" title="MinderhoudIM , SamsomM , OldenburgB . Crohn’s disease, fatigue, and infliximab: Is there a role for cytokines in the pathogenesis of fatigue?. World of Journal of Gastroenterology2007;13(14):2089‐93. ">Minderhoud 2007</a>; <a href="./references#CD012005-bbs2-0029" title="NCT01991314 . Treatment of iron deficiency anaemia in adults and adolescents with inflammatory bowel disease using ferrous sulphate: tolerance and effects on haemoglobin, mood, quality of life and fatigue. clinicaltrials.gov/ct2/show/NCT01991314 (first received 25 November 2013). ">NCT01991314</a>; <a href="./references#CD012005-bbs2-0030" title="NCT02148718 . Rapidity of onset of response to adalimumab in luminal Crohn's disease (RAPIDA Study). clinicaltrials.gov/ct2/show/NCT02148718 (first received 28 May 2014). ">NCT02148718</a>; <a href="./references#CD012005-bbs2-0031" title="NCT02162862 . Treating disrupted sleep in individuals with inflammatory bowel disease: a novel adjunctive therapy for chronic inflammatory illness. clinicaltrials.gov/ct2/show/NCT02162862 (first received 13 June 2014). ">NCT02162862</a>; <a href="./references#CD012005-bbs2-0034" title="PersoonsP , DemyttenaereK , VandenbergheJ , VanOudenhoveL , RugeertsP . The evolution of fatigue in patients with Crohn's disease after treatment with infliximab: a prospective study. Gastroenterology2004;126(4):A476. ">Persoons 2007</a>; <a href="./references#CD012005-bbs2-0044" title="SzigethyE , McAuliffK , StrassburgerM , HashashJ , VachonA , RodeNM , et al. Brief behavioral therapy and bupropion for sleep and fatigue in adolescents and young adults with inflammatory bowel disease. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S210. ">Szigethy 2016</a>). For example, trials were single‐group assignment open trials (<a href="./references#CD012005-bbs2-0029" title="NCT01991314 . Treatment of iron deficiency anaemia in adults and adolescents with inflammatory bowel disease using ferrous sulphate: tolerance and effects on haemoglobin, mood, quality of life and fatigue. clinicaltrials.gov/ct2/show/NCT01991314 (first received 25 November 2013). ">NCT01991314</a>; <a href="./references#CD012005-bbs2-0030" title="NCT02148718 . Rapidity of onset of response to adalimumab in luminal Crohn's disease (RAPIDA Study). clinicaltrials.gov/ct2/show/NCT02148718 (first received 28 May 2014). ">NCT02148718</a>; <a href="./references#CD012005-bbs2-0044" title="SzigethyE , McAuliffK , StrassburgerM , HashashJ , VachonA , RodeNM , et al. Brief behavioral therapy and bupropion for sleep and fatigue in adolescents and young adults with inflammatory bowel disease. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S210. ">Szigethy 2016</a>) or non‐randomised trials (<a href="./references#CD012005-bbs2-0028" title="MinderhoudIM , SamsomM , OldenburgB . Crohn’s disease, fatigue, and infliximab: Is there a role for cytokines in the pathogenesis of fatigue?. World of Journal of Gastroenterology2007;13(14):2089‐93. ">Minderhoud 2007</a>; <a href="./references#CD012005-bbs2-0031" title="NCT02162862 . Treating disrupted sleep in individuals with inflammatory bowel disease: a novel adjunctive therapy for chronic inflammatory illness. clinicaltrials.gov/ct2/show/NCT02162862 (first received 13 June 2014). ">NCT02162862</a>). Three studies were excluded as data from IBD‐specific participants were not presented separately (<a href="./references#CD012005-bbs2-0020" title="FordDC , DahlNV , StraussWE , BarishCF , HetzelDJ , BernardK , et al. Ferumoxytol versus placebo in iron deficiency anaemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders. Clinical and Experimental Gastroenterology2016;9:151‐62. ">Ford 2016</a>; <a href="./references#CD012005-bbs2-0021" title="HetzelD , StraussW , BernardK . IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with gastrointestinal disorders unable to take oral iron: a randomised controlled trial versus iron sucrose. Journal of Crohn's and Colitis2013;7:S204. ">Hetzel 2013b</a>; <a href="./references#CD012005-bbs2-0039" title="ScholtenAM , VermeulenE , Dhonukshe‐RuttenRA , VerhagenT , VisscherA , OlivierA , et al. Surplus vitamin B12 use does not reduce fatigue in patients with irritable bowel syndrome or inflammatory bowel disease: a randomized double‐blind placebo‐controlled trial. Clinical Nutrition European Society for Clinical Nutrition and Metabolism2018;23:48‐53. ">Scholten 2018</a>). </p> <p>Details of the 34 excluded studies are presented in the <a href="./references#CD012005-sec-0157" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012005-sec-0080"> <h5 class="title">Studies awaiting classification</h5> <p>Five studies are awaiting classification following the top‐up search conducted in October 2019 (<a href="./references#CD012005-bbs2-0049" title="GhoshS , AberraF , CrossR , ZhouW , ChenN , LeeWJ , et al. Effect of upadacitinib on patient‐reported symptoms by the new ulcerative colitis symptoms questionnaire (UC‐SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U‐ACHIEVE. Journal of Crohn's and Colitis2019;13:S247‐S248. NCT02819635 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety and efficacy of upadacitinib (ABT‐494) for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. clinicaltrials.gov/ct2/show/NCT02819635 (first received 30 June 2016). ">Ghosh 2019</a>; <a href="./references#CD012005-bbs2-0050" title="LouisE , SandbornWJ , D'HaensG , BaertF , KalabicJ , WallaceK , et al. Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn's disease: phase 2 trial results. Journal of Crohn's and Colitis2019;13:S291‐S292. NCT02031276 . A phase II, multicenter, randomized, double‐blind, multiple dose, placebo‐controlled, parallel‐group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066/ABBV‐066 (risankizumab), and IL‐23 p19 antagonist monoclonal antibody in patients with ,moderately to severely active Crohn's disease who are naïve to, or were previously treated with, anti‐TNF therapy. clinicaltrials.gov/ct2/show/NCT02031276 (first received 9 January 2014). ">Louis 2019</a>; <a href="./references#CD012005-bbs2-0051" title="NCT02709434 . The efficacy of a structured psychoeducational inflammatory bowel disease group on the control of fatigue in an adult outpatient setting for patients with objectively quiescent disease. ClinicalTrials.gov/show/NCT02709434 (first received 16 March 2016). O'ConnorA , RatnakumaranR , WarrenL , PullenD , ErringtonA , GracieDJ , et al. Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. Therapeutic Advances in Chronic Disease2019;10:1‐12. [DOI: 10.1177/2040622319838439] ">O' Connor 2019</a>; <a href="./references#CD012005-bbs2-0052" title="SandsBE , PiresA , GasinkC , LalimanV , HanC , FeaganBG . Post hoc analysis of the impact of ustekinumab treatment on specific items of the Inflammatory Bowel Disease Questionnaire in the Uniti‐1 &amp; 2 programs. Gastroenterology2018;154:S‐811. ">Sands 2018</a>; <a href="./references#CD012005-bbs2-0053" title="ISRCTN13021107 . A randomised controlled trial investigating the feasibility and acceptability of high‐intensity interval training and moderate‐intensity continuous training in adults with inactive or mildly active Crohn’s disease. www.isrctn.com/ISRCTN13021107 (first received 2 December 2015). TewGA , LeightonD , CarpenterR , AndersonS , LangmeadL , RamageJ , et al. High‐intensity interval training and moderate‐intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial. BMC Gastroenterology2019;19(1):19. ">Tew 2019</a>). Two studies are presented in full text and three are published as conference proceedings. Additional information is needed from the study authors and these studies will be assessed for inclusion at the next update of the review. </p> </section> </section> </section> <section id="CD012005-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p>Two of the fourteen included trials (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>) were judged as adequately meeting all criteria (<a href="#CD012005-fig-0002">Figure 2</a>; <a href="#CD012005-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012005-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012005-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012005-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012005-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Details on the risk of bias for each individual trial are located within the '<a href="./references#CD012005-sec-0156" title="">Characteristics of included studies</a>' table. </p> <section id="CD012005-sec-0082"> <h4 class="title">Allocation</h4> <p>All studies were randomised, however, for two studies, the method of sequence generation could not be ascertained as sufficient description of the process was not provided to confirm true randomisation (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). Studies used sequence generation methods such as random number tables (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), interactive voice response system (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>), computer‐generated simple randomisation (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), computer‐generated block randomisation (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), or manual block randomisation (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). </p> <p>Studies also applied measures to conceal allocation using an interactive voice response system (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>), sequential named drug containers of identical appearance provided by a pharmacy (capsule assignment) (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) or sealed opaque envelopes (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). Other studies employed open allocation (high risk of bias) (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) or physical activity advice intervention (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). Concealment of allocation was unclear for the remaining five studies (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) due to insufficient information available. These studies were described as randomised, however convenience allocation may have been employed. </p> </section> <section id="CD012005-sec-0083"> <h4 class="title">Blinding</h4> <p>With regards to performance bias, studies varied from double‐blinded (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), single‐blinded (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) to part‐blinded (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) and unblinded (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). It remained unclear from two studies (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>) if blinding occurred due to limited information provided, although one study stated that the trial was double‐blinded, however, further information was not provided (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). Most drug trials were double‐blinded (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), resulting in a low risk of bias classification. Participants, sponsors, clinical researchers and clinical staff were blinded to the treatment allocation in these studies, whereas only the participants were blinded (single‐blinded) in three studies (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). Personnel administering the intervention were not blinded resulting in an unclear risk of bias classification (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>)<b>.</b> However, in another study, the participants and evaluators, but not the therapist, were blinded to group assignment, therefore, deemed at low risk of bias (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). A high risk of bias was observed in one study which blinded participants and researchers to the capsule (supplement) type, however, were unable to blind personnel to the consultation type due to the nature of the physical activity advice intervention (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Three studies were unblinded due to the inherent psychosocial nature of the interventions (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Although one study (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>) tried to blind outcome assessment undertaken by a gastroenterologist, all studies were judged to have a high risk of bias. </p> <p>The primary outcome of interest, fatigue, is a subjective outcome self‐reported in all studies, therefore, the unblinded (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and part‐blinded (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) studies were classified as at high risk of detection bias. Participants were blinded in the remaining double‐blinded (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) and single‐blinded (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) studies, therefore, these studies were judged to have a low risk of detection bias. An unclear risk of bias was recorded for two studies (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>), as no explicit statement about blinding status of participants, healthcare providers, data collectors and outcome adjudicators was presented. </p> </section> <section id="CD012005-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>There was a relatively low dropout rate for the psychosocial intervention trials (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and loss to follow‐up was balanced across groups with reasons comparable to the pharmacological trials (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), yielding a low risk of bias classification. One study had no loss to follow‐up (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). The remaining two trials provided insufficient information on missing outcome data (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). </p> </section> <section id="CD012005-sec-0085"> <h4 class="title">Selective reporting</h4> <p>Most studies were judged as having a low risk of bias in terms of selective outcome reporting as all information on outcomes was presented and outcomes assessed were reported or provided upon request (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a><a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). However, selective outcome reporting was an issue in the remaining studies, where the results were presented for subgroups only or certain outcomes were not reported. For example, two trial authors provided information on the outcomes upon request (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). However, the findings are only published as conference abstracts at present, therefore, we rated these studies as having unclear risk of bias for selective reporting. One study presented data comparing the intervention group with the overall placebo population control group rather than an IBD placebo control group (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>). Also, one study did not report the fatigue and quality of life scores for the intervention and control groups, but rather, data for a subgroup based on the 25‐hydroxyvitamin D (25OHD) levels were presented (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). Another study presented only percentages for fatigue scores, with no effect sizes or P values reported (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Additional information requested was not provided by trial authors, therefore, these five trials were all classified as having high risk of bias (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Fatigue and quality of life data were not published for one trial (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>), however, we are awaiting outcome data from the trial author, so this trial, therefore, was judged as having unclear risk of bias for selective outcome reporting. </p> </section> <section id="CD012005-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <section id="CD012005-sec-0087"> <h5 class="title">Selection bias</h5> <p>Ten studies reported similar baseline characteristics between treatment groups (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) minimising the potential for selection bias. Unbalanced groups at baseline were noted in one study only (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), so this study was rated as having a high risk of selection bias. It remained unclear from two studies if baseline characteristics of groups differed due to limited or no information reported and so selection bias was rated as being unclear for these studies (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). </p> </section> <section id="CD012005-sec-0088"> <h5 class="title">Use of validated assessment instruments</h5> <p>Ten studies used a validated fatigue assessment instrument to measure fatigue (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), however, in three trials, fatigue was assessed as a subscale or subcomponent of a broader quality of life scale only (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). One study assessed the average frequency and severity of 'tiredness' (fatigue) as a single item from a 10‐item disease symptom diary (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). The validity of single‐item or subscale measures of fatigue are unknown, hence, the reliability of the study findings need to be interpreted with caution. </p> </section> </section> </section> <section id="CD012005-sec-0089"> <h3 class="title" id="CD012005-sec-0089">Effects of interventions</h3> <p>See: <a href="./full#CD012005-tbl-0001"><b>Summary of findings for the main comparison</b> Electroacupuncture compared to no treatment for participants with quiescent IBD</a>; <a href="./full#CD012005-tbl-0002"><b>Summary of findings 2</b> Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD</a>; <a href="./full#CD012005-tbl-0003"><b>Summary of findings 3</b> CBT with therapist support compared to fatigue information leaflet only for participants with IBD</a>; <a href="./full#CD012005-tbl-0004"><b>Summary of findings 4</b> Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD</a>; <a href="./full#CD012005-tbl-0005"><b>Summary of findings 5</b> Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD</a>; <a href="./full#CD012005-tbl-0006"><b>Summary of findings 6</b> Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD</a> </p> <p>The effects of 'pharmacological versus placebo'; 'pharmacological versus pharmacological', 'non‐pharmacological versus usual or standard care', 'non‐pharmacological versus non‐pharmacological' and 'pharmacological versus non‐pharmacological' were the comparisons included. No trial made the remaining comparisons considered eligible for this review<b>.</b> See <a href="./full#CD012005-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012005-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012005-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012005-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD012005-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012005-tbl-0001">summary of findings Table for the main comparison</a>; <a href="#CD012005-tbl-0007">Table 1</a>; <a href="#CD012005-tbl-0008">Table 2</a>; <a href="#CD012005-tbl-0009">Table 3</a>; <a href="#CD012005-tbl-0010">Table 4</a>; <a href="#CD012005-tbl-0011">Table 5</a>; <a href="#CD012005-tbl-0012">Table 6</a>; <a href="#CD012005-tbl-0013">Table 7</a>. The summary of effects of the interventions on the predefined outcomes (fatigue, quality of life and adverse events) of the included trials are presented below. </p> <div class="table" id="CD012005-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with moderately‐to‐severely active disease<br/> <b>Setting:</b> 92 centres in the United States, Europe, Canada, Australia and South Africa<br/> <b>Intervention:</b> adalimumab 40 mg every other week<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adalimumab 40 mg every other week</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐Fatigue<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.3 higher<br/> (1.75 higher to 6.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 Vitality<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 54.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.8 higher<br/> (5.1 lower to 10.7 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 172.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.4 higher<br/> (0.53 lower to 21.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>888 per 1,000<br/> (826 to 930) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.44<br/> (0.86 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (56 to 148) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.56<br/> (0.33 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1,000<br/> (39 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.48<br/> (0.26 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the confidence interval was wide and the fatigue data represented the last‐observation‐carried‐forward when a participant had missing value, dropped out or switched to open‐label therapy. </p> <p><sup>2</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>3</sup> Downgraded one level due to serious imprecision as the number of participants was small. </p> </div> </div> <div class="table" id="CD012005-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> fatigue in inflammatory bowel disease<br/> <b>Setting:</b> 92 centres in the United States, Europe, Canada, Australia and South Africa<br/> <b>Intervention:</b> adalimumab 40 mg weekly<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adalimumab 40 mg weekly</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐Fatigue<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 higher<br/> (0.26 lower to 5.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52 with higher scores indicating less fatigue.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 vitality<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 54.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.2 higher<br/> (4.72 lower to 11.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 172.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.4 higher<br/> (1.63 lower to 20.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>856 per 1,000<br/> (785 to 906) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.08<br/> (0.66 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 per 1,000<br/> (48 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.49<br/> (0.28 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1,000<br/> (24 to 88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.33<br/> (0.15 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the confidence interval was wide and the fatigue data represented the last‐observation‐carried‐forward when a participant had missing value, dropped out or switched to open‐label therapy. </p> <p><sup>2</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>3</sup> Downgraded one level due to serious imprecision as the number of participants was small. </p> </div> </div> <div class="table" id="CD012005-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with moderately‐to‐severely active Crohn's disease<br/> <b>Setting:</b> 92 centres in the United States, Europe, Canada, Australia and South Africa<br/> <b>Intervention:</b> adalimumab maintenance<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adalimumab maintenance</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 Vitality<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 54.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3 higher<br/> (4.25 lower to 10.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating better vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: SF‐36 Physical Component Summary<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 47.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.3 higher<br/> (1.3 lower to 3.99 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 physical component summary scores ranged from 0 to 100, with higher scores indicating better physical quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: SF‐36 Mental Component Summary<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 48.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.2 higher<br/> (1.28 lower to 5.68 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SF‐36 mental component summary scores ranged from 0 to 100, with higher scores indicating better mental quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 172.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.9 higher<br/> (0.4 lower to 20.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>873 per 1,000<br/> (817 to 913) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.24<br/> (0.81 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDra<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 per 1,000<br/> (56 to 131) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.53<br/> (0.33 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 per 1,000<br/> (36 to 93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.40<br/> (0.24 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>2</sup> Downgraded one level due to serious imprecision as the number of events was small. </p> </div> </div> <div class="table" id="CD012005-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AndoSan compared to placebo for participants with mild‐to‐moderately active Crohn's disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>AndoSan compared to placebo for participants with mild‐to‐moderately active Crohn's disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with mild‐to‐moderately active Crohn's disease<br/> <b>Setting:</b> outpatients from a single centre in Oslo, Norway<br/> <b>Intervention:</b> AndoSan<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with AndoSan</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Total Fatigue score<br/> follow‐up: 21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 16.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.63 lower<br/> (3.51 lower to 0.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total fatigue scores ranged from 0 to 33, with higher scores indicating greater fatigue.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 Vitality<br/> follow‐up: 21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 40.61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.68 higher<br/> (1.64 lower to 9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>2</sup> Downgraded by one level due to high risk of bias for allocation bias (open allocation). </p> </div> </div> <div class="table" id="CD012005-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Ferric maltol compared to placebo for participants in remission or mild‐to‐moderately active Crohn's disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ferric maltol compared to placebo for participants in remission or mild‐to‐moderately active Crohn's disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants in remission or mild‐to‐moderately active Crohn's disease<br/> <b>Setting:</b> outpatients from 4 centres in Austria, Germany, Hungary and the UK<br/> <b>Intervention:</b> ferric maltol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ferric maltol</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 vitality<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 53.23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.31 lower<br/> (17.15 lower to 1.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 176</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.7 higher<br/> (7.89 lower to 15.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>717 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>582 per 1,000<br/> (397 to 749) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.55<br/> (0.26 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDRA<br/> follow‐up: mean 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (5 to 202) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.14 to 7.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 per 1,000<br/> (45 to 334) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.69<br/> (0.52 to 5.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> </div> </div> <div class="table" id="CD012005-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Guided stress management compared to conventional medical treatment for participants with Crohn's disease in remission</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Guided stress management compared to conventional medical treatment for participants with Crohn's disease in remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with Crohn's disease in remission<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> guided stress management<br/> <b>Comparison:</b> conventional medical treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional medical treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with guided stress management</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Average frequency of tiredness<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 51.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/> (30.77 lower to 30.77 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average frequency of tiredness was calculated as the number of symptomatic days divided by total reported days x 100. Higher mean scores indicated higher average frequency of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Severity of tiredness<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 higher<br/> (0.39 lower to 0.99 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The severity of tiredness scores ranged from 0 to 3, with higher scores indicating greater severity of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels due to serious imprecision as the number of participants was small and the confidence interval was wide. </p> <p><sup>2</sup> Downgraded by two levels due to high risk of bias for most criteria. </p> </div> </div> <div class="table" id="CD012005-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Self‐directed stress management compared to conventional medical treatment for participants with Crohn's disease in remission</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Self‐directed stress management compared to conventional medical treatment for participants with Crohn's disease in remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with Crohn's disease in remission<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> self‐directed stress management<br/> <b>Comparison:</b> conventional medical treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional medical treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with self‐directed stress management</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Average frequency symptom (tiredness)<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 51.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 29.6 lower<br/> (58.68 lower to 0.52 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average frequency symptom (tiredness) was calculated as the number of symptomatic days divided by the total reported days x 100. Higher scores indicated greater average frequency of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Severity of tiredness<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 lower<br/> (0.98 lower to 0.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of tiredness scores ranged from 0 to 3, with higher scores indicating greater severity of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>2</sup> Downgraded by two levels due to high risk of bias for most criteria. </p> </div> </div> <section id="CD012005-sec-0090"> <h4 class="title">Pharmacological interventions versus placebo</h4> <p>Eight trials made this comparison (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), however fatigue data were only available for four of the trials (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>;<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). In four trials, the mean difference in the primary and secondary outcomes could not be calculated, as data were not available. These comparisons included ferumoxytol versus placebo (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>); vedolizumab maintenance versus placebo (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>); and vitamin D3 versus placebo (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>). </p> <section id="CD012005-sec-0091"> <h5 class="title">a. Adalimumab versus placebo</h5> <p>The effect of adalimumab therapy was assessed in one trial (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). Adalimumab was administered either 40 mg every other week (eow) or 40 mg weekly. In this review, dichotomous data were presented for both dosing regimens individually and also combined (adalimumab maintenance therapy). Continuous data were presented for the adalimumab maintenance therapy group and the adalimumab 40 mg eow group only, to avoid a unit of analysis error with multi‐arm trials. As it was not possible to calculate a mean and standard deviation for each placebo comparator, the adalimumab 40 mg eow was selected as the dose group that reflects clinical practice. </p> <section id="CD012005-sec-0092"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue, as measured using the FACIT‐F and SF‐36 vitality subscale, was assessed in one trial (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). The mean difference between adalimumab maintenance therapy and the placebo groups could not be calculated for FACIT‐F, as summary data were not published or available upon request. However, fatigue data, as measured using the FACIT‐F, were available for randomised responders (participants who had previously responded [achieved clinically meaningful change in disease activity by week 4] to open‐label adalimumab induction therapy) only. Although fatigue was also assessed for all randomised participants, data were not available upon request. Furthermore, the FACIT‐F data represented the last‐observation‐carried‐forward when a participant had a missing value, dropped out, or switched to open‐label therapy. A difference was found in fatigue levels between adalimumab 40 mg eow, compared to the placebo at the 56‐week follow‐up, as measured by the FACIT‐F. The mean fatigue score after 56 weeks of treatment was 36.8 in the in the adalimumab 40 mg eow group compared to 32.5 in the placebo group (MD 4.30, 95% CI 1.75 to 6.85, very low‐certainty evidence) (<a href="./references#CD012005-fig-0011" title="">Analysis 2.1</a>). </p> <p>Fatigue, as measured using the SF‐36 vitality subscale, revealed no difference between adalimumab maintenance therapy and the adalimumab 40 mg eow group, compared to the placebo group, for all randomised participants or for randomised previous responders (low‐certainty evidence) (<a href="./references#CD012005-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD012005-fig-0012" title="">Analysis 2.2</a>). </p> </section> <section id="CD012005-sec-0093"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life data, as measured using the SF‐36 and IBDQ, were reported in one trial (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). There was no difference in quality of life scores, as measured by the SF‐36 between the adalimumab maintenance therapy group and adalimumab 40 mg eow group, compared to the placebo group, for all randomised participants or randomised previous responders (low‐certainty evidence) (<a href="./references#CD012005-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD012005-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD012005-fig-0013" title="">Analysis 2.3</a>; <a href="./references#CD012005-fig-0014" title="">Analysis 2.4</a>). However, when quality of life was measured using the disease‐specific IBDQ, the mean quality of life score after 56 weeks of treatment was 187.1 in the adalimumab maintenance therapy group compared to 173.3 in the placebo group for randomised responders (MD 13.80, 95% CI 1.99 to 25.61, low‐certainty evidence) (<a href="./references#CD012005-fig-0007" title="">Analysis 1.4</a>). </p> <p>The treatment‐emergent adverse events during double‐blind treatment for the intention‐to‐treat subjects revealed that there was no difference in adverse events for adalimumab maintenance therapy, adalimumab 40 mg eow and adalimumab 40 mg weekly compared to placebo (<a href="./references#CD012005-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD012005-fig-0016" title="">Analysis 2.6</a>; <a href="./references#CD012005-fig-0024" title="">Analysis 3.6</a>). Serious adverse events and withdrawal due to adverse events were reported in 9% (24/260) and 7% (18/260) of participants in the adalimumab 40 mg eow group compared to 15% (20/130) and 13% (17/130) in the placebo group, respectively (OR 0.56, 95% CI 0.30 to 1.06 and OR 0.49, 95% CI 0.25 to 1.00, moderate‐certainty evidence) (<a href="./references#CD012005-fig-0017" title="">Analysis 2.7</a>; <a href="./references#CD012005-fig-0018" title="">Analysis 2.8</a>). However, the adalimumab maintenance and adalimumab 40 mg weekly groups were less likely to experience serious adverse events and withdrawal due to adverse events compared to placebo. Serious adverse events were reported in 8.7% (45/517) and 8.2% (21/257) of participants in the treatment groups compared to 15.3% (40/261) and 15.4% (20/130) of participants in the placebo groups, respectively (OR 0.53, 95% CI 0.33 to 0.83 and OR 0.49, 95% CI 0.25 to 0.94, moderate‐certainty evidence) (<a href="./references#CD012005-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD012005-fig-0025" title="">Analysis 3.7</a>). Withdrawal due to adverse events was reported in 5.8% (30/517) and 4.7% (12/257) of participants in the treatment groups compared to 13.4% (35/261) and 13.1% (17/130) of participants in the placebo groups for the adalimumab maintenance therapy and the adalimumab 40 mg weekly groups, respectively (OR 0.40, 95% CI 0.24 to 0.66 and OR 0.33 95% CI 0.15 to 0.70, moderate‐certainty evidence) (<a href="./references#CD012005-fig-0010" title="">Analysis 1.7</a>; <a href="./references#CD012005-fig-0026" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD012005-sec-0094"> <h5 class="title">b. AndoSan<sup>TM</sup> versus placebo </h5> <section id="CD012005-sec-0095"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the Fatigue Questionnaire and SF‐36 vitality subscale, were available in two trials (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). Data from these trials were pooled as they were assessed as clinically homogenous with regards to participants, interventions, and outcomes, with I² = 0% for total fatigue score and I² = 61% for SF‐36 vitality. At 21 days post‐intervention, there was no difference in fatigue, as measured by the Fatigue Questionnaire, between the AndoSan<sup>TM</sup> group compared to the placebo group for those with ulcerative colitis (MD ‐1.80, 95% CI ‐4.39 to 0.79, low‐certainty evidence) (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>) or Crohn's disease (MD ‐1.36,95% CI ‐4.07 to 1.35, low‐certainty evidence) (<a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) (<a href="./references#CD012005-fig-0027" title="">Analysis 4.1</a>). Similar results were found when fatigue was measured using the SF‐36 vitality subscale (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). At 21 days post‐intervention, there was no difference in fatigue scores between AndoSan<sup>TM</sup> and the placebo group for those with ulcerative colitis (MD 8.60, 95% CI ‐1.09 to 18.29, low‐certainty evidence) (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>) and those with Crohn's disease (MD ‐3.72, 95% CI ‐15.31 to 7.87, low‐certainty evidence) (<a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>) (<a href="./references#CD012005-fig-0028" title="">Analysis 4.2</a>). </p> </section> <section id="CD012005-sec-0096"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life was assessed using the SF‐36, however, total physical component summary scores and mental component summary scores were not calculated. Rather, findings from the eight health dimensions of the scale were presented (author information). </p> <p>Adverse events were assessed by the trial author via interviews with participants at all visits. Although participants tolerated AndoSan<sup>TM</sup> well, the trial authors did not record AEs (author information). </p> </section> </section> <section id="CD012005-sec-0097"> <h5 class="title">c. Ferric maltol versus placebo</h5> <section id="CD012005-sec-0098"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the SF‐36 vitality subscale, were available in one trial (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>). At 12 weeks post‐intervention, there was a difference in the mean vitality scores between the ferric maltol and placebo groups. The mean vitality score was 43.92 in the treatment group compared to 53.23 in the placebo group, with higher scores indicating better vitality (less fatigue) (MD ‐9.31, 95% CI ‐17.15 to ‐1.47, low‐certainty evidence) (<a href="./references#CD012005-fig-0029" title="">Analysis 5.1</a>). </p> </section> <section id="CD012005-sec-0099"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life data, as measured using the IBDQ, were available in one trial (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>). At 12 weeks post‐intervention, there was no difference in quality of life scores between the ferric maltol group and the placebo group (MD 3.70, 95% CI ‐7.89 to 15.29, low‐certainty evidence) (<a href="./references#CD012005-fig-0030" title="">Analysis 5.2</a>). </p> <p>Adverse events were reported in 51% (35/60) of participants in the ferric maltol group compared to 71% (43/60) of participants in the placebo group (OR 0.55, 95% CI 0.26 to 1.18, low‐certainty evidence) (<a href="./references#CD012005-fig-0031" title="">Analysis 5.3</a>). Serious adverse events were reported in 8% (8/60) of participants in the ferric maltol group compared to 13% (6/60) of participants in the placebo group (OR 1.00,95% CI 0.14 to 7.34, low‐certainty evidence) (<a href="./references#CD012005-fig-0032" title="">Analysis 5.4</a>). No difference in withdrawal due to adverse events was found between the groups (OR 1.69, 95% CI 0.52 to 5.51, low‐certainty evidence) (<a href="./references#CD012005-fig-0033" title="">Analysis 5.5</a>). </p> </section> </section> </section> <section id="CD012005-sec-0100"> <h4 class="title">Pharmacological interventions versus pharmacological interventions</h4> <p>One trial made this comparison, however, the mean difference in the primary and secondary outcomes could not be calculated as data were not available (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>). </p> </section> <section id="CD012005-sec-0101"> <h4 class="title">Non‐pharmacological interventions versus usual or standard care</h4> <p>Three trials made this comparison (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). </p> <section id="CD012005-sec-0102"> <h5 class="title">a. Electroacupuncture versus no treatment</h5> <section id="CD012005-sec-0103"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the FACIT‐F, were available in one trial (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). There was a difference in fatigue levels found between the electroacupuncture group, compared to the control group. The mean fatigue score after eight weeks of treatment was 33.2 in the electroacupuncture group compared to 25.2 in the control group, with higher scores indicating better vitality (less fatigue) (MD 8.00, 95% CI 6.45 to 9.55, low‐certainty evidence) (<a href="./references#CD012005-fig-0034" title="">Analysis 6.1</a>). The difference in fatigue levels at the week 16 follow‐up could not be calculated. The summary data for the control group were not available at follow‐up, as the group was offered open‐label electroacupuncture treatment. </p> </section> <section id="CD012005-sec-0104"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life data, as measured using the IBDQ‐9, were available in one trial (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). At the week eight follow‐up, there was a difference in IBDQ‐9 scores between the electroacupuncture group compared to the control group. The mean quality of life score after eight weeks of treatment was 61.5 in the treatment group, compared to 57.0 in the control group (MD 4.50, 95% CI 3.37 to 5.63, low‐certainty evidence) (<a href="./references#CD012005-fig-0035" title="">Analysis 6.2</a>). The IBDQ‐9 summary data were not available at the week 16 follow‐up to calculate the mean difference, as the group was offered open‐label electroacupuncture treatment. No adverse events, serious adverse events and withdrawal due to adverse events were reported by participants in the electroacupuncture or control groups. </p> </section> </section> <section id="CD012005-sec-0105"> <h5 class="title">b. Electroacupuncture versus sham electroacupuncture</h5> <section id="CD012005-sec-0106"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the FACIT‐F, were available in one trial (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). At the week eight and 16 follow‐up, there was a difference in fatigue scores between the electroacupuncture group and the sham electroacupuncture group. The mean vitality score after eight weeks of treatment was 33.2 in the electroacupuncture group compared to 28.1 in the sham electroacupuncture group, with higher scores indicating better vitality (less fatigue) (MD 5.10, 95% CI 3.49 to 6.71, low‐certainty evidence) (<a href="./references#CD012005-fig-0039" title="">Analysis 7.1</a>). At 16‐week follow‐up, the mean vitality score was 31.4 in the electroacupuncture group compared to 28.8 in the sham electroacupuncture group (MD 2.60, 95% CI 0.74 to 4.46, low‐certainty evidence) (<a href="./references#CD012005-fig-0039" title="">Analysis 7.1</a>). </p> </section> <section id="CD012005-sec-0107"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life data, as measured using the IBDQ‐9, were available in one trial (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). A mean difference was found in the quality of life scores following treatment at week eight and at the week 16 follow‐up. The mean quality of life score after eight weeks of treatment was 61.5 in the electroacupuncture group compared to 57.8 in the sham electroacupuncture group (MD 3.70, 95% CI 2.66 to 4.74, low‐certainty evidence) (<a href="./references#CD012005-fig-0040" title="">Analysis 7.2</a>). At 12‐week follow‐up, the mean quality of life score was 60.8 in the electroacupuncture group compared to 58.6 in the sham electroacupuncture group (MD 2.20, 95% CI 0.98 to 3.42, low‐certainty evidence) (<a href="./references#CD012005-fig-0040" title="">Analysis 7.2</a>). One adverse event was reported in the sham electroacupuncture group (<a href="./references#CD012005-fig-0041" title="">Analysis 7.3</a>). No serious adverse events were reported by participants in either group (<a href="./references#CD012005-fig-0042" title="">Analysis 7.4</a>). There was one withdrawal due to adverse events in the sham electroacupuncture group (<a href="./references#CD012005-fig-0043" title="">Analysis 7.5</a>). </p> </section> </section> <section id="CD012005-sec-0108"> <h5 class="title">c. Guided stress management programme versus conventional medical treatment</h5> <section id="CD012005-sec-0109"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, measured as the average frequency of tiredness and the severity of tiredness, were available in one trial (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). At post‐intervention and 12‐month follow‐up, there were no differences in the average frequency of tiredness in the guided stress management programme compared to the conventional medical treatment group (MD ‐22.10, 95% CI ‐55.47 to 11.27 and MD 0.00, 95% CI ‐30.77 to 30.77, respectively, very low‐certainty evidence) (<a href="./references#CD012005-fig-0044" title="">Analysis 8.1</a>). Likewise, the severity of tiredness was not different in the guided stress management group, compared to the conventional medical treatment group post‐intervention or at 12‐month follow‐up (MD ‐0.40, 95% CI ‐1.18 to 0.38 and MD 0.30, 95% CI ‐0.39 to 0.99, very low‐certainty evidence) (<a href="./references#CD012005-fig-0045" title="">Analysis 8.2</a>), respectively. </p> </section> <section id="CD012005-sec-0110"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life and adverse events were not assessed in this trial (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). The author stated that no adverse events were reported (author information). </p> </section> </section> <section id="CD012005-sec-0111"> <h5 class="title">d. Self‐directed stress management programme versus conventional medical treatment</h5> <section id="CD012005-sec-0112"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, measured as the average frequency of tiredness and the severity of tiredness, were available in one trial (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). At post‐intervention, there was no difference in the average frequency of tiredness between the self‐directed stress management group and the conventional medical treatment group (MD ‐17.20, 95% CI ‐50.91 to 16.51, very low‐certainty evidence), However, at 12 months follow‐up, a difference in the average frequency of tiredness was found. The average frequency of tiredness scores was 21.8 in the self‐directed stress management group compared to 51.4 in the conventional medical treatment group (MD ‐29.60, 95% CI ‐58.68 to ‐0.52, very low‐certainty evidence) (<a href="./references#CD012005-fig-0046" title="">Analysis 9.1</a>). There was no difference in the severity of tiredness post‐intervention (MD ‐0.20, 95% CI ‐1.01 to 0.61, very low‐certainty evidence), or at 12‐month follow‐up (MD ‐0.30, 95% CI ‐0.98 to 0.38, very low‐certainty evidence) (<a href="./references#CD012005-fig-0047" title="">Analysis 9.2</a>). </p> </section> <section id="CD012005-sec-0113"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life and adverse events were not assessed in this trial (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). The author stated that no adverse events were reported (author information). </p> </section> </section> <section id="CD012005-sec-0114"> <h5 class="title">e. Solution‐focused therapy versus care‐as‐usual</h5> <section id="CD012005-sec-0115"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the CIS‐F and FSS‐9, were available in one trial (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). The mean difference in fatigue between the solution‐focused therapy and care‐as‐usual groups could not be calculated because standard summary data were not reported. However, when data from the CIS‐F were presented as a dichotomous variable, the solution‐focused therapy group showed a greater reduction in fatigue across the first six months compared with the CAU group (P &lt; 0.001). No significant differences between the two groups were found at nine months. </p> </section> <section id="CD012005-sec-0116"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life was assessed in one trial (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). However, the mean difference in quality of life scores between the solution‐focused therapy and care‐as‐usual groups could not be calculated because summary data were not reported. Adverse events were not assessed in this trial (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). </p> </section> </section> </section> <section id="CD012005-sec-0117"> <h4 class="title">Non‐pharmacological interventions versus non‐pharmacological interventions</h4> <p>One trial made this comparison (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>). </p> <section id="CD012005-sec-0118"> <h5 class="title">a. Cognitive behavioural therapy with therapist support versus fatigue information leaflet </h5> <section id="CD012005-sec-0119"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the IBD‐F, were available in one trial (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>). At month three follow‐up, there was no difference in IBD‐F section I scores and IBD‐F section II scores between the cognitive behavioural therapy with therapist support group and the fatigue information leaflet group. The mean fatigue level score was 7.29 in the treatment group compared to 9.45 in the control group (MD ‐2.16, 95% CI ‐6.13 to 1.81, very low‐certainty evidence) (<a href="./references#CD012005-fig-0048" title="">Analysis 10.1</a>). The mean impact of the fatigue score was 25.71 in the cognitive behavioural therapy with therapist support group compared to 47.33 in the fatigue information leaflet group (MD ‐21.62, 95% CI ‐45.02 to 1.78, very low‐certainty evidence) (<a href="./references#CD012005-fig-0049" title="">Analysis 10.2</a>). </p> </section> <section id="CD012005-sec-0120"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>Quality of life data, as measured using the UK‐IBDQ, were available in one trial (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>). No difference in quality of life scores were found between the cognitive behaviour therapy with therapist support group, compared to the fatigue information leaflet group, at the month three follow‐up (MD 0.19, 95% CI ‐9.32 to 9.70, very low‐certainty evidence) (<a href="./references#CD012005-fig-0050" title="">Analysis 10.3</a>). Adverse events were not assessed in this trial (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>). </p> </section> </section> </section> <section id="CD012005-sec-0121"> <h4 class="title">Multimodular intervention</h4> <p>One trial used multimodular comparisons (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). This 2 x 2 factorial RCT examined six comparisons, namely: </p> <p>1. No physical activity advice plus omega 3 versus no physical activity advice plus placebo; </p> <p>2. Physical activity advice plus omega 3 versus no physical activity advice plus omega 3; </p> <p>3. Physical activity advice plus placebo versus no physical activity advice plus placebo;</p> <p>4. Physical activity advice plus omega 3 versus physical activity advice plus placebo;</p> <p>5. Physical activity advice plus omega 3 versus no physical activity advice plus placebo;</p> <p>6. Physical activity advice plus placebo versus no physical activity advice plus omega.</p> <p>In order to avoid a unit of analysis error, it was not possible to calculate mean and standard deviations for each placebo comparator, therefore the following three key comparisons were selected: </p> <section id="CD012005-sec-0122"> <h5 class="title">a. Physical activity advice plus omega 3 versus no physical activity advice plus omega 3 </h5> <section id="CD012005-sec-0123"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the FACIT‐F, MFI and IBD‐F, were available in one trial (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). At the 12‐week follow‐up, there was no difference in fatigue levels between the physical activity advice plus omega 3 group, compared to the no physical activity advice plus omega 3 group, as measured using the FACIT‐F (MD 6.40, 95% CI ‐1.80 to 14.60, very low‐certainty evidence) (<a href="./references#CD012005-fig-0051" title="">Analysis 11.1</a>) or the MFI (MD ‐ 0.50, 95% CI ‐3.88 to 2.88, very low‐certainty evidence) (<a href="./references#CD012005-fig-0052" title="">Analysis 11.2</a>). Likewise, there was no difference between the groups when fatigue was measured using the disease‐specific IBD‐F scale section I (MD ‐ 3.10, 95% CI ‐6.67 to 0.47, very low‐certainty evidence) (<a href="./references#CD012005-fig-0053" title="">Analysis 11.3</a>) and section II (MD ‐13.10, 95% CI ‐29.37 to 3.17, very low‐certainty evidence) (<a href="./references#CD012005-fig-0054" title="">Analysis 11.4</a>). </p> </section> <section id="CD012005-sec-0124"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>At the 12‐week follow‐up, there was no difference in quality of life scores between the physical activity advice plus omega 3 group, and the no physical activity advice plus omega 3 group (MD 4.00, 95% CI ‐18.46 to 26.46, very low‐certainty evidence) (<a href="./references#CD012005-fig-0055" title="">Analysis 11.5</a>). </p> <p>At the 12‐week follow‐up, there were five reported adverse events in the physical activity advice plus omega 3 group, namely, epigastric pain (n = 1), bloating (n = 1), headache (n = 1), leg pain (n = 1) and feeling unwell (n = 1). There were fourteen reported adverse events in the no physical activity advice plus omega 3 group, namely, epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 2), nausea and vomiting (n = 3), IBD flare (n = 1), pins and needles (n = 1), joint pain (n = 1), ankle injury (n = 1), rash (n = 1) and feeling unwell (n = 2). Serious adverse events and withdrawal due to adverse events were not reported. </p> </section> </section> <section id="CD012005-sec-0125"> <h5 class="title">b. Physical activity advice plus placebo versus no physical activity advice plus placebo</h5> <section id="CD012005-sec-0126"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>Fatigue data, as measured using the FACIT‐F, MFI and IBD‐F, were available in one trial (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). At the 12‐week follow‐up, there was no difference in fatigue levels between the physical activity advice plus placebo group, and the no physical activity advice plus placebo group, as measured using the FACIT‐F (MD 2.70, 95% CI ‐2.48 to 7.88, very low‐certainty evidence) (<a href="./references#CD012005-fig-0056" title="">Analysis 12.1</a>), however a difference was identified when measured using the MFI. The mean fatigue score was 12.7 in the treatment group compared to 15.3 in the control group, with higher scores indicating greater fatigue (MD ‐ 2.60, 95% CI ‐4.70 to ‐0.50, very low‐certainty evidence) (<a href="./references#CD012005-fig-0057" title="">Analysis 12.2</a>). There was no difference between the groups when fatigue was measured using the disease‐specific IBD‐F scale section I (MD ‐ 1.70, 95% CI ‐4.04 to 0.64, very low‐certainty evidence) (<a href="./references#CD012005-fig-0058" title="">Analysis 12.3</a>) and section II (MD ‐8.50, 95% CI ‐21.57 to 4.57, very low‐certainty evidence) (<a href="./references#CD012005-fig-0059" title="">Analysis 12.4</a>). </p> </section> <section id="CD012005-sec-0127"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>At the 12‐week follow‐up, there was no difference in quality of life scores between the physical activity advice plus placebo group and the no physical activity advice plus placebo group (MD 9.00, 95% CI ‐15.72 to 33.72, very low‐certainty evidence) (<a href="./references#CD012005-fig-0060" title="">Analysis 12.5</a>). </p> <p>At the 12‐week follow‐up, there were four reported adverse events in the physical activity advice plus placebo group, namely, epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 1), and nausea and vomiting (n = 1). There were five reported adverse events in the no physical activity advice plus placebo group, namely epigastric pain (n = 2), diarrhoea (n = 1), headache (n = 1), and molluscum (n = 1). Serious adverse events and withdrawal due to adverse events were not reported. </p> </section> </section> <section id="CD012005-sec-0128"> <h5 class="title">c. Physical activity advice plus placebo versus no physical activity advice plus omega 3 </h5> <section id="CD012005-sec-0129"> <h6 class="title">Primary outcome ‐ Fatigue</h6> <p>At the 12‐week follow‐up, a difference in fatigue levels was found between the physical activity advice plus placebo group, and the no physical activity advice plus omega 3 group, as measured using the FACIT‐F. The mean vitality scores after 12 weeks of treatment was 41.1 in the physical activity advice plus placebo group compared to 32.1 in the no physical activity advice plus omega 3, with higher scores indicating greater vitality (less fatigue) (MD 9.00, 95% CI 1.64 to 16.36, very low‐certainty evidence) (<a href="./references#CD012005-fig-0061" title="">Analysis 13.1</a>). No difference was identified when fatigue was measured using the MFI (MD ‐1.40, 95% CI ‐4.39 to 1.59, low‐certainty evidence) (<a href="./references#CD012005-fig-0062" title="">Analysis 13.2</a>). There was no difference between the groups when fatigue was measured using the disease‐specific IBD‐F scale section I, however, the mean level of fatigue scores after 12 weeks of treatment was 6.8 for the physical activity advice plus placebo group compared to 9.6 for the no physical activity advice plus omega 3 group (MD ‐2.80, 95% CI ‐5.93 to 0.33, very low‐certainty evidence) (<a href="./references#CD012005-fig-0063" title="">Analysis 13.3</a>). A difference was evident between the groups when measured by section II of the IBD‐F. The mean impact of the fatigue scores was 19.4 for the physical activity advice plus placebo group compared to 34.8 in the no physical activity advice plus omega 3 group (MD ‐15.40, 95% CI ‐30.51 to ‐0.29, very low‐certainty evidence) (<a href="./references#CD012005-fig-0064" title="">Analysis 13.4</a>). </p> </section> <section id="CD012005-sec-0130"> <h6 class="title">Secondary outcomes ‐ Quality of life and adverse events</h6> <p>At the 12‐week follow‐up, there was no difference in quality of life scores between the physical activity advice plus placebo group, and the no physical activity advice plus omega 3 group (MD 4.00, 95% CI ‐18.20, to 26.20, very low‐certainty evidence) (<a href="./references#CD012005-fig-0065" title="">Analysis 13.5</a>). </p> <p>At the 12‐week follow‐up, there were four reported adverse events in the physical activity advice plus placebo group, namely, epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 1), and nausea and vomiting (n = 1). There was fourteen reported adverse events in the no physical activity advice plus omega 3 group, namely, epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 2), nausea and vomiting (n = 3), IBD flare (n = 1), pins and needles (n = 1), joint pain (n = 1), ankle injury (n = 1), rash (n = 1) and feeling unwell (n = 2). Serious adverse events and withdrawal due to adverse events were not reported. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012005-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012005-sec-0131"></div> <section id="CD012005-sec-0132"> <h3 class="title" id="CD012005-sec-0132">Summary of main results</h3> <p>This systematic review included fourteen randomised controlled trials (3741 participants) that evaluated the efficacy and safety of different pharmacological and non‐pharmacological interventions on fatigue in IBD. The fourteen trials in the review included nine pharmacological, four non‐pharmacological and one multimodular trial. Only four trials assessed fatigue as a primary outcome (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Outcome data on fatigue were not available for analysis from all fourteen trials, therefore, the findings of this review are based on 1344 participants in nine trials. Only two of the studies were pooled, due to the diversity and limited number of studies for each intervention. </p> <p>Given the high prevalence and burden of fatigue in IBD, there is very limited evidence on interventions that help fatigue. In the <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a> trial, at week 56 the mean fatigue scores were lower in the adalimumab 40 mg administered every other week group (36.8) than in the placebo group (32.5) in participants with Crohn's disease who were already known to respond to adalimumab treatment, with higher scores indicating less fatigue. The mean difference between the groups was 4.30 points and this is likely to be a clinically meaningful improvement in fatigue levels (<a href="./references#CD012005-bbs2-0092" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>; <a href="./references#CD012005-bbs2-0091" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. ">Cella 2002</a>). However, the GRADE analysis indicated that the overall certainty of the evidence for this outcome was very low due to due to serious inconsistency and very serious imprecision as the confidence interval was wide and the fatigue data measured using the FACIT‐F represented the last‐observation‐carried‐forward when a participant had missing values, dropped out or switched to open‐label therapy. No difference in fatigue was evident for adalimumab maintenance therapy or adalimumab 40 mg administered every other week in all randomised participants. Results must be interpreted with caution as the fatigue findings differ when measured using the FACIT‐F and the SF‐36 vitality subscale, and the indication for the intervention was disease activity, rather than the primary outcome of this review. Further research is needed before any firm conclusions can be drawn about potential fatigue benefits with adalimumab 40 mg administered every other week in patients with Crohn's disease. </p> <p>The evidence suggests that ferric maltol results in a slight increase in fatigue in patients with Crohn's disease or ulcerative colitis, in remission or with mild‐to‐moderate disease activity (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>). Mean fatigue scores were lower in the ferric maltol group (43.92) compared to placebo (53.23), with higher scores indicating better vitality (less fatigue). The mean difference between ferric maltol and placebo groups was 9.31 points and this is likely to be a minimally important differences in fatigue in people with Crohn's disease (<a href="./references#CD012005-bbs2-0094" title="CoteurG , FeaganB , KeiningerDL , KosinskiM . Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease. Alimentary Pharmacology &amp; Therapeutics2009;29(9):1032‐41. ">Coteur 2009</a>). However, these results should be interpreted with caution as the GRADE analysis indicated that the overall certainty of the evidence was low due to sparse data and a wide confidence interval, therefore, further research is needed. </p> <p>Results from one trial on self‐directed stress management intervention suggest that the average frequency of tiredness is lower compared to the standard care group, with a mean difference of 29.6 points found at 12 months (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). However, there was no difference in the severity of tiredness between the self‐directed stress management group and those receiving standard care. The assessment measure used has not been validated and it is unclear whether observed improvements in the frequency of tiredness are clinically meaningful. Thus, we are very uncertain about the effects of self‐directed stress management on fatigue. </p> <p>There is evidence to suggest that electroacupuncture may result in a large reduction in fatigue and increase in quality of life compared to no treatment after eight weeks of treatment and also compared to sham electroacupuncture post‐treatment and eight weeks following treatment (<a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>). The mean difference between electroacupuncture and control groups post‐treatment was 8 points and this is likely to be a clinically meaningful improvement in fatigue levels (<a href="./references#CD012005-bbs2-0092" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>; <a href="./references#CD012005-bbs2-0091" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. ">Cella 2002</a>). The scores were not available for the control group to calculate the mean difference between the groups at week 16, as participants reporting no improvement in fatigue (FACIT‐F score &lt; 40) at week eight were offered open electroacupuncture in this cross‐over design trial. Mean fatigue scores were also higher in the electroacupuncture group compared to the sham electroacupuncture group both at week eight and week 16 follow‐up, with higher scores indicating less fatigue. A mean difference of 5.10 points and 2.60 points was found at week eight and week 16, respectively. This suggests a likely clinically meaningful improvement in fatigue post‐treatment, however, the difference may not be clinically important eight weeks following treatment (<a href="./references#CD012005-bbs2-0091" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. ">Cella 2002</a>; <a href="./references#CD012005-bbs2-0092" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>). The GRADE analysis indicated that the overall certainty of the evidence supporting these results were low due to sparse data and wide confidence intervals. Further research is needed before any strong conclusions can be drawn on the efficacy of electroacupuncture on fatigue. </p> <p>We found that physical activity advice may also reduce fatigue but the evidence is very uncertain. One 2 x 2 factorial RCT (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) examined six comparisons, therefore, in order to avoid a unit of analysis error, only three key comparisons were selected. The mean differences in fatigue scores between the physical activity advice plus omega 3 and no physical activity advice plus omega 3 groups using the different fatigue scales (FACIT‐F 6.40; MFI ‐0.50; IBDF Section I ‐3.10; IBDF Section II ‐13.10) were not statistically significant, however, may be clinically meaningful for the FACIT‐F scale (<a href="./references#CD012005-bbs2-0091" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. ">Cella 2002</a>; <a href="./references#CD012005-bbs2-0092" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>). It is unclear whether the observed improvements in fatigue for the IBDF scale are important, due to the lack of clearly defined minimally important thresholds. In contrast, the mean difference scores were lower for the physical activity advice plus placebo and no physical activity advice plus placebo comparison across the FACIT‐F (MD 2.7), MFI (‐2.6), IBDF Section I (‐1.70) and IBDF Section II (‐8.50) scales. Although, a statistically significant difference was found, as measured by the MFI scale, the mean difference may not be clinically important (<a href="./references#CD012005-bbs2-0116" title="GoligherEC , PouchotJ , BrantR , KheraniRB , Avina‐ZubietaJA , LacailleD , et al. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. Journal of Rheumatology2008;35(4):635‐42. ">Goligher 2008</a>; <a href="./references#CD012005-bbs2-0138" title="PouchotJ , KheraniRB , BrantR , LacailleD , LehmanAJ , EnsworthS , et al. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. Journal of Clinical Epidemiology2008;61:705‐13. ">Pouchot 2008</a>). For the third comparison, it was found that the mean fatigue scores were higher in the physical activity advice plus placebo group (41.1) than the no physical activity advice plus omega 3 group (32.1) using the FACIT‐F scale, with higher scores indicating less fatigue. The mean fatigue scores were lower in the physical activity advice plus placebo group (MFI 12.7; IBDF Section I 6.8; IBDF Section II 19.4) than the no physical activity advice group plus omega 3 group (MFI 14.1; IBDF Section I 9.6; IBDF Section II 34.8), with lower scores indicating less fatigue. The mean difference for the FACIT‐F scale (MD 9.00) is likely to be clinically meaningful (<a href="./references#CD012005-bbs2-0091" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. ">Cella 2002</a>; <a href="./references#CD012005-bbs2-0092" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>), however not important based on the MFI mean difference (MD ‐ 1.40) (<a href="./references#CD012005-bbs2-0116" title="GoligherEC , PouchotJ , BrantR , KheraniRB , Avina‐ZubietaJA , LacailleD , et al. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. Journal of Rheumatology2008;35(4):635‐42. ">Goligher 2008</a>; <a href="./references#CD012005-bbs2-0138" title="PouchotJ , KheraniRB , BrantR , LacailleD , LehmanAJ , EnsworthS , et al. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. Journal of Clinical Epidemiology2008;61:705‐13. ">Pouchot 2008</a>) and unclear for the IBDF scale (IBDF Section I MD ‐ 2.80; IBDF Section II MD ‐ 15.40). Results must be interpreted with caution as the fatigue findings differ when measured using different fatigue scales and the overall GRADE analysis indicated that the certainty of the evidence supporting these results is low due to high risk of bias, sparse data and wide confidence intervals. </p> <p>Partial data were available from some of the fatigue outcomes assessed in the solution‐focused therapy (SFT) trial (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). There is evidence to suggest that SFT shows a greater reduction in fatigue at six months follow‐up compared with care‐as‐usual, however, data were reported in a non‐standard way and the study rated as high risk of bias for selective reporting, therefore, we are very uncertain about the efficacy and safety of solution‐focused therapy on fatigue, </p> <p>No difference in fatigue levels were found for any of the other comparisons, including adalimumab 40 mg weekly (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>), AndoSan<sup>TM</sup> (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), guided stress management (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>), physical activity advice and/or omega 3 (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) and cognitive behavioural therapy with therapist support (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>). </p> <p>Fatigue data were not available for the trials investigating the effect of customised combination therapy (tight control management) (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>), vedolizumab maintenance therapy (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), vitamin D3 (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>) or ferumoxytol (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>). This was primarily due to fatigue not being a primary outcome in these trials. </p> <p>Secondary outcomes relevant to our review, namely quality of life and adverse events, were both assessed in nine trials (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a><a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). One trial (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>) assessed adverse events only; three trials assessed quality of life only (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>) and one trial (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>) assessed neither secondary outcomes relevant to our review. There was no difference in physical or mental quality of life, as measured using a generic quality of life scale, for adalimumab maintenance therapy or adalimumab 40 mg administered every other week compared to placebo (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). In contrast, when quality of life was measured using a disease‐specific measure, results suggest a difference in scores for the adalimumab maintenance therapy and adalimumab 40 mg administered every other week compared to placebo, for randomised previous responders only. Mean fatigue scores were higher in the adalimumab maintenance group (187.1) and the adalimumab 40 mg administered every other week group (187.9) than in the placebo group (173.3) at 56 weeks in participants with Crohn's disease who were already known to respond to adalimumab treatment, with higher scores indicating better quality of life. However, the mean differences between the groups were 13.80 and 14.60 points, respectively, and this is likely to not be a clinically meaningful improvement in quality of life (<a href="./references#CD012005-bbs2-0092" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>; <a href="./references#CD012005-bbs2-0091" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. ">Cella 2002</a>). The evidence suggests that electroacupuncture may result in a large increase in quality of life, compared to control and sham electroacupuncture. The mean quality of life scores were higher in the electroacupuncture group (61.5) than the control group (57) and sham electroacupuncture (57.8) at week eight. The mean quality of life scores were also higher in the electroacupuncture group (60.8) compared to the sham electroacupuncture group (58.6) at week 16. However, it is unclear whether the observed improvements in quality of life are clinically important, due to the lack of clearly defined minimally important difference thresholds for the IBDQ‐9 scale. The GRADE analysis indicated that the overall certainty of the evidence supporting these results on quality of life was low due to sparse data and wide confidence intervals. Further research is needed before any strong conclusions can be drawn on the efficacy and safety of adalimumab maintenance therapy, adalimumab 40 mg administered every other week and electroacupuncture on quality of life. </p> <p>No differences in quality of life were found for ferric maltol (<a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>), cognitive behavioural therapy with therapist support (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>), and the physical activity advice and omega 3 comparisons (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). Although assessed, quality of life data were not available for the trials investigating the effect of customised combination therapy (tight control management) (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>), vedolizumab maintenance therapy (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>), vitamin D3 (<a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>), solution‐focused therapy (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), and guided and self‐directed stress management (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). Total physical and mental component quality of life scores were not reported in two trials (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). </p> <p>In terms of safety, there was no difference in adverse events reported in the three adalimumab treatment groups compared to placebo, however, the adalimumab maintenance and adalimumab 40 mg weekly groups were significantly less likely to experience serious adverse events and withdrawal due to adverse events, compared to control, for all randomised participants (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). The multimodular trial (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>) reported a range of adverse events, including epigastric pain, diarrhoea, bloating, nausea and vomiting, IBD flare, headache, pins and needles, joint pain, ankle injury, leg pain, rash, molluscum and feeling unwell. Adverse events varied across groups, with the no physical activity advice plus omega 3 group reporting more adverse events (n = 14), compared to the other three groups (n = 4 or n = 5). These adverse events were considered to be mild in nature. This study did not report serious adverse events or withdrawal due to adverse events. There was no difference in adverse events reported for any of the other trials. Additional information from the trial authors revealed that there were no adverse events reported by participants involved in the guided and self‐directed stress management (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>) and the AndoSan<sup>TM</sup> trials (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). Adverse events were not reported in the solution‐focused therapy trial (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>), cognitive behavioural therapy with therapist support trial (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>) or for the randomised responders in the adalimumab trial (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). </p> <p>The evidence presented in this review is limited due the diversity of interventions, missing data, low or very low evidence of certainty due to single studies, small sample sizes, and unclear or high risk of bias in trials (see '<a href="./references#CD012005-sec-0156" title="">Characteristics of included studies</a>'). The results reported in this review must therefore be interpreted with caution. Most studies included in this review were published in the last five years, with a large number of ongoing trials (n = 30) also identified as potentially eligible in future updates, indicating the growing interest in IBD fatigue. </p> </section> <section id="CD012005-sec-0133"> <h3 class="title" id="CD012005-sec-0133">Overall completeness and applicability of evidence</h3> <p>This review included fourteen studies (3741 participants), however, as outcome data on fatigue were not available for all included trials, the findings are based on 1344 participants in nine trials, so completeness of evidence is a concern. Due to insufficient and non‐standard reporting, fatigue data were available for analysis from only eight of the 14 eligible trials. Data on the two secondary outcomes were presented in five of the trials. Although some additional information was obtained from the trial authors, insufficient data was a difficulty in this review. For example, data on the primary outcome relevant to this review, although assessed, were not available for analysis in four trials (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>). Furthermore, one trial presented fatigue data as estimates and effect sizes for the intervention and control groups at each time point, rather than standard reporting of mean and standard deviation scores (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Pharmacological companies have ownership of data for one of the large pharmacological trials and a data request has been submitted and is awaited (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>). Three of the nine eligible trials did not present baseline participant characteristics for the groups (<a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). However, most studies did present sufficient baseline information on age, gender, disease type, disease activity or disease duration. </p> <p>The studies tended to include participants with Crohn's disease only, or both ulcerative colitis or Crohn's disease, whereas the focus of trials on only individuals with ulcerative colitis remains limited (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>). Crohn's disease is a more complex disease and it has been previously suggested that this disease type may be more responsive to therapy, as Crohn's disease is associated with higher levels of fatigue and greater impairment in quality of life. Studies with mixed populations did not report subgroup analysis according to disease type. As most interventions were not specifically targeted at IBD fatigue, there was no subgroup analysis on those with other pre‐existing fatigue related comorbidities, for example, depression and anxiety. Furthermore, subgroup analysis was not possible in this review due to the small sample sizes and diversity across trials. </p> <p>As most participants were not recruited because of fatigue, it seems likely in some studies that participants experienced low levels of fatigue at baseline and perhaps may have had limited scope for improvement in fatigue levels. For example, in the two trials investigating the effect of AndoSan<sup>TM</sup> on fatigue in participants with ulcerative colitis (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>) and Crohn's disease (<a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), the baseline total fatigue scores were relatively low. </p> <p>There is some evidence of the effect of pharmacological interventions on IBD fatigue, however, there were fewer studies examining the efficacy of non‐pharmacological interventions. The cost implications and potential side effects of pharmacological therapies suggest there may be difficulty using such type of treatment specifically for managing IBD fatigue. In contrast, four of the five non‐pharmacological interventions were specifically designed and developed for managing IBD fatigue (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). More research is needed, in particular, studies specifically developed and targeted at managing IBD fatigue in well‐defined patient groups. For example, a specific type of therapy may work best for participants with Crohn's disease, rather than those with ulcerative colitis, in improving fatigue. </p> <p>The duration of interventions ranged from 21 days to 56 weeks. Given the multidimensional nature of fatigue and the complexities of IBD, the potential benefit of longer intervention periods should also be explored. More research is needed to be able to draw any firm conclusions about the efficacy and safety of pharmacological and non‐pharmacological interventions on fatigue in individuals with IBD. </p> </section> <section id="CD012005-sec-0134"> <h3 class="title" id="CD012005-sec-0134">Quality of the evidence</h3> <p>The quality of evidence presented in this review is limited. Two studies were assessed as high quality on all criteria (<a href="#CD012005-fig-0002">Figure 2</a>; <a href="#CD012005-fig-0003">Figure 3</a>). Our assessment of risk of bias was considerably compromised by insufficient publication of information. Most studies used adequate procedures for random sequence generation. Methods of allocation concealment was rated low risk in only five trials. Most pharmacological trials were either double‐blinded (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) or single‐blinded (<a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>). In contrast, most non‐pharmacological interventions were unblinded, due to the inherent nature of the type of intervention (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Therefore, the trend of positive effect found in these studies may have been as a result of a placebo response. Standard care or care‐as‐usual were frequently used as the control, however, limited information on the care received or the visits schedule was typically provided. There is little evidence if and to what extent conditions between the intervention and control groups were kept similar in non‐pharmacological trials, in order to reduce the risk of performance bias. </p> <p>The primary outcome of this review was a subjective, self‐reported outcome, therefore, detection bias was rated high for all unblinded trials and low for double‐ and single‐ (participant) blinded trials. There were no concerns over attrition bias in most studies, however, the small sample size in many trials was problematic. Selection bias was not an issue in terms of comparable baseline characteristics of groups. This may be as a result of the random sampling strategies used in trials. There were concerns over the quality of reporting in six trials, where data were presented insufficiently (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>; <a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>) and reported in a non‐standard way (<a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). Overall, our assessment, based on GRADE analyses, suggests that the certainty of the evidence supporting the outcomes of this review ranges was low or very low. As a result of this uncertainty, no firm conclusions can be drawn regarding the efficacy and safety of pharmacological and non‐pharmacological interventions on fatigue in IBD. </p> </section> <section id="CD012005-sec-0135"> <h3 class="title" id="CD012005-sec-0135">Potential biases in the review process</h3> <p>We performed a comprehensive literature search to minimise bias related to study selection. We are confident that our search strategy has identified all eligible pharmacological and non‐pharmacological randomised controlled trials assessing fatigue or loss of energy as a primary or secondary outcome in IBD published up until October 2019. Our search was limited to English, therefore, there may be a language bias. Two authors reviewed the studies for inclusion and exclusion, extracted data independently, and reviewed study quality. Additional information was retrieved from authors for eight of the 14 eligible trials (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>; <a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>; <a href="./references#CD012005-bbs2-0006" title="GascheC , AhmadT , TulassayZ , BaumgartDC , BokemeyerB , BüningC , et al. Ferric Maltol is effective in correcting iron deficiency anaemia in patients with inflammatory bowel disease: results from a Phase‐3 clinical trial program. Inflammatory Bowel Diseases2015;21(3):579‐88. ">Gasche 2015</a>; <a href="./references#CD012005-bbs2-0008" title="HortaD , Sanchez‐LloansiM , LiraA , VilloriaA , TeggiachiM , GarciaD , et al. A prospective randomised study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. United European Gastroenterology Journal2017;5(Supplement 1):A293‐4. ">Horta 2017</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>; <a href="./references#CD012005-bbs2-0012" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of a medicinal agaricus blazei murill‐based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single‐blinded placebo controlled study. PlOS One2016;11(3):e0150191. ">Therkelsen 2016a</a>; <a href="./references#CD012005-bbs2-0013" title="TherkelsenSP , HetlandG , LybergT , LygrenI , JohnsonE . Effect of the medicinal agaricus blazei murill‐based mushroom extract, AndoSanTM, on symptoms, fatigue and quality of life in patients with Crohn’s Disease in a randomized single‐blinded placebo controlled study. PLOS One2016;11(7):e0159288. ">Therkelsen 2016b</a>), with one request for additional information still outstanding (<a href="./references#CD012005-bbs2-0003" title="ColombelJF , PanaccioneR , BossuytP , LukasM , BaertF , VaňásekT , et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet2017;390(10114):2779‐89. NCT01235689 . An open‐label, multicenter, efficacy and safety study to evaluate two treatment algorithms in subjects with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/NCT01235689 (first received 5 November 2010). PanaccioneR , ColombelJF , BossuytP , BaertF , VanasekT , DanaliogluA , et al. DOP071 Tight control with adalimumab‐based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM. Journal of Crohn's and Colitis2018;12:S078‐9. ">Colombel 2017</a>) and five studies identified from the top‐up search run in October 2019 awaiting assessment needing additional information from the trial authors. Some studies where insufficient data were reported were included in the review demonstrating presence of reporting bias (<a href="./references#CD012005-bbs2-0004" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. NCT00783718 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT00783718 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. ">Feagan 2013</a>; <a href="./references#CD012005-bbs2-0007" title="HetzelD , BarishC , DahlN , BernardK , LauG , StraussW . Efficacy and safety of intravenous Ferunoxytol for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Inflammatory Bowel Diseases2013;19(Supplement 1):S81‐2. HetzelD , FordD , DahlN , StraussW . Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): efficacy, safety and health‐related quality of life (HRQOL). Journal of Crohn's and Colitis2014;8:S248‐9. ">Hetzel 2013a</a>; <a href="./references#CD012005-bbs2-0010" title="NCT01792388 . Vitamin D and its effects on inflammation and intestinal permeability in Crohn's disease in remission. clinicaltrials.gov/ct2/show/NCT01792388 (first received 15 February 2013). RafteryTC , HealyM , CoxG , McNamaraD , O’ SullivanM . Vitamin D supplementation improves muscles strength, fatigue and quality of life in patients with Crohn’s disease in remission: results of a randomised double‐blind placebo‐controlled study. Gastroenterology2013;144(5):S227. ">Raftery 2013</a>; <a href="./references#CD012005-bbs2-0011" title="NCT00783692 . A phase 3, randomized, placebo‐controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's Disease. clinicaltrials.gov/ct2/show/study/NCT00783692 (first received 2 November 2008). RubinDT , TudorD , KhalidJM , PatelH . P570 Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: results from GEMINI trial data. Journal of Crohn's and Colitis2018;12(Supplement 1):S394‐5. SandbornWJ , FeaganBG , RutgeertsP , HanauerS , ColombelJF , SandsBE , et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2013;369(8):711‐21. ">Sandborn 2013</a>; <a href="./references#CD012005-bbs2-0014" title="VogelaarL , Van't SpijkerA , TimmanR , VanTilburgA , BacD , KuipersEJ , et al. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial. Journal of Crohn's and Colitis2013;7:S211‐12. VogelaarL , Van’t SpijkerA , TimmanR , VanTilburgAJP , BacD , VogelaarT , et al. Fatigue management in patients with IBD: a randomised controlled trial. Gut2014;63:911‐8. ">Vogelaar 2014</a>). However, as data on the primary outcome remain unavailable, these studies did not contribute to the overall findings of the review. </p> <p>Limitations of this systematic review include the diversity of interventions, the limited number of studies with a small number of participants and sparse data. Only one pooled analysis was undertaken. The small sample sizes in the trials may have been insufficient to detect a small effect. All studies that assessed fatigue or loss of energy as a primary or secondary outcome using a generic or disease‐specific fatigue scale, a subscale of a broader questionnaire or as a single question were deemed eligible for inclusion. All generic and disease‐specific measures used in the trials demonstrated adequate psychometric properties, however, caution needs to be exercised when interpreting findings measured using non‐validated subscales or single‐item measures. For example, one trial assessed the average frequency and severity of tiredness using a single item on a Crohn's disease symptom diary (<a href="./references#CD012005-bbs2-0005" title="García‐VegaE , Fernandez‐RodriguezC . A stress management programme for Crohn’s disease. Behaviour Research and Therapy2004;42(4):367‐83. ">García‐Vega 2004</a>). In future updates of this review, further consideration needs to be given to the inclusion of studies that use subscales or single‐item measures of fatigue. As there are a lack of clearly defined minimal clinically important differences (MCID) for some fatigue measures established in the IBD literature, this limits the interpretation of results and conclusions drawn. Three review authors (WCD, MA, CN) were involved in two eligible trials included in this review. These authors were not involved in extracting data or conducting 'Risk of bias' assessments for these trials (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>; <a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). </p> </section> <section id="CD012005-sec-0136"> <h3 class="title" id="CD012005-sec-0136">Agreements and disagreements with other studies or reviews</h3> <p>A review has appraised the management of fatigue in IBD (<a href="./references#CD012005-bbs2-0101" title="Czuber‐DochanW , ReamE , NortonC . Review article: description and management of fatigue in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2013;37(5):505‐16. ">Czuber‐Dochan 2013a</a>). Similar to the present review, a paucity of evidence was found. It supported the findings regarding the potential benefit of adalimumab, stress management and solution‐focused therapy for fatigue in IBD. Furthermore, the evidence from this review is broadly in agreement with some other Cochrane reviews on fatigue management in other chronic illnesses. For example, Cochrane reviews suggest that exercise therapy may be an effective and safe treatment for reducing fatigue in adults with chronic fatigue syndrome (<a href="./references#CD012005-bbs2-0129" title="LarunL , BrurbergK , Odgaard‐JensenJ , PriceJR . Exercise therapy for chronic fatigue syndrome. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD003200.pub7] ">Larun 2017</a>), multiple sclerosis (<a href="./references#CD012005-bbs2-0118" title="HeineM , Van dePortI , RietbergMB , VanWegenEEH , KwakkelG . Exercise therapy for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD009956.pub2] ">Heine 2015</a>), rheumatoid arthritis (<a href="./references#CD012005-bbs2-0096" title="CrampF , HewlettS , AlmeidaC , KirwanJR , ChoyEHS , ChalderT , et al. Non‐pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008322.pub2] ">Cramp 2013</a>) and people with breast and prostate cancer both during and after cancer treatment (<a href="./references#CD012005-bbs2-0095" title="CrampF , Byron‐DanielJ . Exercise for the management of cancer‐related fatigue in adults. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD006145.pub3] ">Cramp 2012</a>), which supports the findings of this review in relation to the potential benefit of physical activity advice (<a href="./references#CD012005-bbs2-0009" title="McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega‐3 supplementation. Journal of Crohn's and Colitis2016;10:S370‐1. McNellyAS , NathanI , MontiM , GrimbleGK , NortonC , BredinF , et al. The effect of increasing physical activity and/or omega‐3 supplementation on fatigue in inflammatory bowel disease. Gastrointestinal Nursing2016;14(8):39‐50. ">McNelly 2016</a>). A Cochrane review evaluating the effect of biologic therapies on fatigue in adults with rheumatoid arthritis found a small to moderate improvement (<a href="./references#CD012005-bbs2-0084" title="AlmeidaC , ChoyEHS , HewlettS , KirwanJR , CrampF , ChalderT , et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD008334] ">Almeida 2016</a>), which is in agreement with the findings of this review on adalimumab treatment (<a href="./references#CD012005-bbs2-0002" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. LoftusEV , FeaganBG , ColombelJ‐F , RubinDT , WuEQ , YuAP , et al. Effects of adalimumab maintenance therapy on health‐related quality of life of patients with Crohn’s disease: patient‐reported outcomes of the CHARM Trial. American Journal of Gastroenterology2008;103(7):3132‐41. RubinD , RutgeertsP , ColombelJ , WuE , YuA , ChaoJ , et al. Adalimumab maintenance therapy and health related quality of life in TNT‐antagonist‐naïve patients with Crohn’s disease. Journal of the Canadian Association of Gastroenterology2009;23(1):S118. ">Colombel 2007</a>). Other Cochrane reviews have found no specific drugs can be recommended as an effective treatment of fatigue in palliative care patients with advanced chronic diseases (<a href="./references#CD012005-bbs2-0135" title="MückeM , Mochamat , CuhlsH , Peuckmann‐PostV , MintonO , StoneP , et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2015, Issue 5. [DOI: 10.1002/14651858.CD006788.pub3] ">Mücke 2015</a>) and multiple sclerosis (<a href="./references#CD012005-bbs2-0141" title="PucciE , Brañas TatoP , D'AmicoR , GiulianiG , SolariA , TausC . Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002818.pub2] ">Pucci 2007</a>; <a href="./references#CD012005-bbs2-0148" title="TejaniAM , WasdellM , SpiwakR , RowellG , NathwaniS . Carnitine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD007280.pub3] ">Tejani 2012</a>). </p> <p>Cochrane reviews have also demonstrated the benefit of psychosocial interventions in managing fatigue in rheumatoid arthritis (<a href="./references#CD012005-bbs2-0096" title="CrampF , HewlettS , AlmeidaC , KirwanJR , ChoyEHS , ChalderT , et al. Non‐pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008322.pub2] ">Cramp 2013</a>) and people with cancer receiving active treatment (<a href="./references#CD012005-bbs2-0115" title="GoedendorpMM , GielissenMFM , VerhagenCAHHVM , BleijenbergG . Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006953.pub2] ">Goedendorp 2009</a>). In particular, cognitive behavioural therapy (<a href="./references#CD012005-bbs2-0140" title="PriceJR , MitchellE , TidyE , HunotV . Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD001027.pub2] ">Price 2008</a>) and educational interventions (<a href="./references#CD012005-bbs2-0087" title="BennettS , PigottA , BellerEM , HainesT , MeredithP , DelaneyC . Educational interventions for the management of cancer‐related fatigue in adults. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD008144.pub2] ">Bennett 2016</a>) have shown an effect on fatigue in adults with chronic fatigue syndrome and cancer, respectively. There is no evidence in this review suggesting that cognitive behavioural therapy may be beneficial in managing fatigue, however this trial (<a href="./references#CD012005-bbs2-0001" title="ArtomM , Czuber‐DochanW , SturtJ , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue with a nested qualitative element: study protocol for a randomised controlled trial. Trials2017;18:213. ArtomM , Czuber‐DochanW , SturtJ , ProudfootH , NortonC . Cognitive behavioural therapy for the management of inflammatory bowel disease‐fatigue: a feasibility randomised controlled trial. Pilot Feasibility Studies2019;5(145). [DOI: https://doi.org/10.1186/s40814‐019‐0538‐y] ISRCTN17917944 . Management of inflammatory bowel disease‐fatigue: a pilot cognitive‐behavioural therapy interventional study. http://www.isrctn.com/ISRCTN17917944 (first received 2 September 2016). ">Artom 2018</a>) was a pilot with a limited sample size. Furthermore, there is no evidence available from our review regarding the effectiveness of educational interventions on fatigue in IBD, which may be a useful strategy that could be incorporated into routine care of individuals with IBD, if proven effective. Similar to our review, Cochrane reviews investigating the effectiveness and safety of pharmacological and non‐pharmacological interventions on fatigue in the area of primary brain tumours (<a href="./references#CD012005-bbs2-0103" title="DayJ , Yust‐KatzS , CachiaD , WefelJ , KatzLH , TremontI , et al. Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD011376.pub2] ">Day 2016</a>), amyotrophic lateral sclerosis (<a href="./references#CD012005-bbs2-0114" title="GibbonsC , PagniniF , FriedeT , YoungCA . Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2018, Issue 1. [DOI: 10.1002/14651858.CD011005.pub2] ">Gibbons 2018</a>) and Parkinson's disease (<a href="./references#CD012005-bbs2-0108" title="ElbersRG , VerhoefJ , VanWegenEEH , BerendseHW , KwakkelG . Interventions for fatigue in Parkinson's disease. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD010925.pub2] ">Elbers 2015</a>) have found insufficient and low‐quality evidence, resulting in no firm conclusion being reached. This suggests that further research also needs to be conducted in the area of fatigue management across other chronic illnesses. Due to the complex nature of fatigue, it appears likely that the optimal management of fatigue would require a multidimensional approach. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012005-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012005-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012005-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012005-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 1 Fatigue: SF‐36 Vitality." data-id="CD012005-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 1 Fatigue: SF‐36 Vitality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 2 Quality of life: SF‐36 PCS." data-id="CD012005-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 2 Quality of life: SF‐36 PCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 3 Quality of life: SF‐36 MCS." data-id="CD012005-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 3 Quality of life: SF‐36 MCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 4 Quality of life: IBDQ." data-id="CD012005-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 4 Quality of life: IBDQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 5 Adverse events." data-id="CD012005-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 6 Serious AEs." data-id="CD012005-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 6 Serious AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adalimumab maintenance versus placebo, Outcome 7 Withdrawal due to AEs." data-id="CD012005-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Adalimumab maintenance versus placebo, Outcome 7 Withdrawal due to AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 1 Fatigue: FACIT‐ F." data-id="CD012005-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 1 Fatigue: FACIT‐ F.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 2 Fatigue: SF‐36 Vitality." data-id="CD012005-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 2 Fatigue: SF‐36 Vitality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 3 Quality of life: SF‐36 PCS." data-id="CD012005-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 3 Quality of life: SF‐36 PCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 4 Quality of life: SF‐36 MCS." data-id="CD012005-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 4 Quality of life: SF‐36 MCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 5 Quality of life: IBDQ." data-id="CD012005-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 5 Quality of life: IBDQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 6 Adverse events." data-id="CD012005-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 7 Serious AEs." data-id="CD012005-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 7 Serious AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 8 Withdrawal due to AEs." data-id="CD012005-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 8 Withdrawal due to AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 1 Fatigue: FACIT‐Fatigue." data-id="CD012005-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 1 Fatigue: FACIT‐Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 2 Fatigue: SF‐36 vitality." data-id="CD012005-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 2 Fatigue: SF‐36 vitality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 3 Quality of life: SF‐36 PCS." data-id="CD012005-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 3 Quality of life: SF‐36 PCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 4 Quality of life: SF‐36 MCS." data-id="CD012005-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 4 Quality of life: SF‐36 MCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 5 Quality of life: IBDQ." data-id="CD012005-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 5 Quality of life: IBDQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 6 Adverse events." data-id="CD012005-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 7 Serious AEs." data-id="CD012005-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 7 Serious AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 8 Withdrawal due to AEs." data-id="CD012005-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 8 Withdrawal due to AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 AndoSan versus placebo, Outcome 1 Fatigue: Total Fatigue Score." data-id="CD012005-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 AndoSan versus placebo, Outcome 1 Fatigue: Total Fatigue Score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 AndoSan versus placebo, Outcome 2 Fatigue: SF‐36 Vitality subscale." data-id="CD012005-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 AndoSan versus placebo, Outcome 2 Fatigue: SF‐36 Vitality subscale.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Ferric maltol versus placebo, Outcome 1 Fatigue: SF‐36 Vitality subscale." data-id="CD012005-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Ferric maltol versus placebo, Outcome 1 Fatigue: SF‐36 Vitality subscale.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Ferric maltol versus placebo, Outcome 2 Quality of life: IBDQ." data-id="CD012005-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Ferric maltol versus placebo, Outcome 2 Quality of life: IBDQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Ferric maltol versus placebo, Outcome 3 Adverse events." data-id="CD012005-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Ferric maltol versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Ferric maltol versus placebo, Outcome 4 Serious AEs." data-id="CD012005-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Ferric maltol versus placebo, Outcome 4 Serious AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Ferric maltol versus placebo, Outcome 5 Withdrawal due to AEs." data-id="CD012005-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Ferric maltol versus placebo, Outcome 5 Withdrawal due to AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Electroacupuncture versus no treatment, Outcome 1 Fatigue: FACIT‐F." data-id="CD012005-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Electroacupuncture versus no treatment, Outcome 1 Fatigue: FACIT‐F.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Electroacupuncture versus no treatment, Outcome 2 Quality of life: IBDQ‐9." data-id="CD012005-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Electroacupuncture versus no treatment, Outcome 2 Quality of life: IBDQ‐9.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Electroacupuncture versus no treatment, Outcome 3 Adverse events." data-id="CD012005-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Electroacupuncture versus no treatment, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Electroacupuncture versus no treatment, Outcome 4 Serious AEs." data-id="CD012005-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Electroacupuncture versus no treatment, Outcome 4 Serious AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Electroacupuncture versus no treatment, Outcome 5 Withdrawal due to AEs." data-id="CD012005-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Electroacupuncture versus no treatment, Outcome 5 Withdrawal due to AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 1 Fatigue: FACIT‐F." data-id="CD012005-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 1 Fatigue: FACIT‐F. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 2 Quality of life: IBDQ‐9." data-id="CD012005-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 2 Quality of life: IBDQ‐9. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 3 Adverse events." data-id="CD012005-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 3 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 4 Serious AEs." data-id="CD012005-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 4 Serious AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 5 Withdrawal due to AEs." data-id="CD012005-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 5 Withdrawal due to AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Guided stress management versus conventional medical treatment, Outcome 1 Fatigue: Average frequency symptom (tiredness)." data-id="CD012005-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Guided stress management versus conventional medical treatment, Outcome 1 Fatigue: Average frequency symptom (tiredness). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Guided stress management versus conventional medical treatment, Outcome 2 Fatigue: Average severity of tiredness." data-id="CD012005-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Guided stress management versus conventional medical treatment, Outcome 2 Fatigue: Average severity of tiredness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Self‐directed stress management versus conventional medical treatment, Outcome 1 Fatigue: Average frequency of tiredness." data-id="CD012005-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Self‐directed stress management versus conventional medical treatment, Outcome 1 Fatigue: Average frequency of tiredness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Self‐directed stress management versus conventional medical treatment, Outcome 2 Fatigue: Average severity of tiredness." data-id="CD012005-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Self‐directed stress management versus conventional medical treatment, Outcome 2 Fatigue: Average severity of tiredness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 CBT with therapist support versus fatigue information leaflet only, Outcome 1 Fatigue: IBD‐F Section I." data-id="CD012005-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 CBT with therapist support versus fatigue information leaflet only, Outcome 1 Fatigue: IBD‐F Section I. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 CBT with therapist support versus fatigue information leaflet only, Outcome 2 Fatigue: IBD‐F Section II." data-id="CD012005-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 CBT with therapist support versus fatigue information leaflet only, Outcome 2 Fatigue: IBD‐F Section II. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 CBT with therapist support versus fatigue information leaflet only, Outcome 3 Quality of life: UK‐IBDQ." data-id="CD012005-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 CBT with therapist support versus fatigue information leaflet only, Outcome 3 Quality of life: UK‐IBDQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 1 Fatigue: FACIT‐F." data-id="CD012005-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 1 Fatigue: FACIT‐F. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 2 Fatigue: MFI." data-id="CD012005-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 2 Fatigue: MFI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 3 Fatigue: IBD‐F Section I." data-id="CD012005-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 3 Fatigue: IBD‐F Section I. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 4 Fatigue: IBD‐F Section II." data-id="CD012005-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 4 Fatigue: IBD‐F Section II. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 5 Quality of life: IBDQ." data-id="CD012005-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Physical activity advice plus omega 3 versus no physical activity advice plus omega 3, Outcome 5 Quality of life: IBDQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 1 Fatigue: FACIT‐F." data-id="CD012005-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 1 Fatigue: FACIT‐F. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 2 Fatigue: MFI." data-id="CD012005-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 2 Fatigue: MFI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 3 Fatigue: IBD‐F Section I." data-id="CD012005-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 3 Fatigue: IBD‐F Section I. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 4 Fatigue: IBD‐F Section II." data-id="CD012005-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 4 Fatigue: IBD‐F Section II. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 5 Quality of life: IBDQ." data-id="CD012005-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Physical activity advice plus placebo versus no physical activity advice plus placebo, Outcome 5 Quality of life: IBDQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 1 Fatigue: FACIT‐F." data-id="CD012005-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 1 Fatigue: FACIT‐F. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 2 Fatigue: MFI." data-id="CD012005-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 2 Fatigue: MFI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 3 Fatigue: IBD‐F Section I." data-id="CD012005-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 3 Fatigue: IBD‐F Section I. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 4 Fatigue: IBD‐F Section II." data-id="CD012005-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 4 Fatigue: IBD‐F Section II. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012005-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/urn:x-wiley:14651858:media:CD012005:CD012005-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_t/tCD012005-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 5 Quality of life: IBDQ." data-id="CD012005-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Physical activity advice plus placebo versus no physical activity advice plus omega 3, Outcome 5 Quality of life: IBDQ. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/media/CDSR/CD012005/image_n/nCD012005-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012005-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Electroacupuncture compared to no treatment for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Electroacupuncture compared to control for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> electroacupuncture<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with electroacupuncture</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐Fatigue<br/> follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 25.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8 higher<br/> (6.45 higher to 9.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue. The difference in fatigue levels at the week‐16 follow‐up could not be calculated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ‐9<br/> follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 57.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.5 higher<br/> (3.37 higher to 5.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ‐9 scores ranged from 9 to 63, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small and the confidence interval was wide. </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision as the number of participants was small and an unvalidated outcome measure was used. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Electroacupuncture compared to no treatment for participants with quiescent IBD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012005-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> electroacupuncture<br/> <b>Comparison:</b> sham electroacupuncture </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham electroacupuncture</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with electroacupuncture</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 28.8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.6 higher<br/> (0.74 higher to 4.46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ‐9<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 58.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.2 higher<br/> (0.98 higher to 3.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ‐9 scores ranged from 9 to 63, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.32<br/> (0.01 to 8.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One adverse event was reported in the sham acupuncture group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety evaluations occurred throughout the treatment period; no events were reported in either group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.32<br/> (0.01 to 8.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was one withdrawal due to adverse events in the sham acupuncture group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision; small number of participants from a single study and the confidence interval was wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012005-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CBT with therapist support compared to fatigue information leaflet only for participants with IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>CBT with therapist support compared to fatigue information leaflet only for participants with IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> CBT with therapist support<br/> <b>Comparison:</b> fatigue information leaflet only </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fatigue information leaflet only</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CBT with therapist support</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section I<br/> follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 9.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.16 lower<br/> (6.13 lower to 1.81 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section II<br/> Scale from: 0 to 120<br/> follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 47.33</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 21.62 lower<br/> (45.02 lower to 1.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: UK‐IBDQ<br/> follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 95.7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.19 higher<br/> (9.32 lower to 9.7 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK‐IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision; small number of participants from a single study and the confidence interval was wide. </p> <p><sup>2</sup> Downgraded one level due to risk of bias in blinding of participants and personnel and blinding in outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CBT with therapist support compared to fatigue information leaflet only for participants with IBD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012005-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> physical activity advice plus omega 3<br/> <b>Comparison:</b> no physical activity advice plus omega 3 </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no physical activity advice plus omega 3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with physical activity advice plus omega 3</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.4 higher<br/> (1.8 lower to 14.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: MFI<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 14.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.5 lower<br/> (3.88 lower to 2.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI scores ranged from 0 to 84, with higher scores indicating greater fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section I<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 9.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.1 lower<br/> (6.67 lower to 0.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section II<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 34.8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 13.1 lower<br/> (29.37 lower to 3.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life assessed with: IBDQ</p> <p>follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean QoL score was 167</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 4.00 higher (18.46 lower to 26.46 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: Medication diary<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were five reported adverse events in the physical activity advice plus omega 3 group and 14 adverse events in the control group, including epigastric pain, bloating, and nausea and vomiting. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were recorded in the medication diary and assessed by the researcher during the 6 follow‐up contact time points. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small, confidence interval was wide and pre‐protocol analyses used. </p> <p><sup>2</sup> Downgraded one level as high risk of bias for blinding of participants and personnel and blinding of outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012005-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> physical activity advice plus placebo<br/> <b>Comparison:</b> no physical activity advice plus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no physical activity advice plus placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with physical activity advice plus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 38.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.7 higher<br/> (2.48 lower to 7.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: MFI<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 15.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.6 lower<br/> (4.7 lower to 0.5 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI scores ranged from 0 to 84, with higher scores indicating greater fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section I<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 8.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.7 lower<br/> (4.04 lower to 0.64 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBD‐F Section II<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue was 27.9</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.5 lower<br/> (21.57 lower to 4.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: assessed with: Medication diary<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were four reported adverse events in the physical activity advice plus placebo group and five reported adverse events in the no physical activity advice plus placebo group, including epigastric pain, diarrhoea, bloating, nausea and vomiting, headache, and molluscum </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were recorded in the medication diary and assessed by the researcher during the 6 follow‐up contact time points. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small, the confidence interval was wide and per protocol analyses used. </p> <p><sup>2</sup> Downgraded one level due to high risk of bias for blinding of participants and personnel and blinding of outcome assessments. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012005-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with quiescent IBD<br/> <b>Setting:</b> outpatients from a single centre in the United Kingdom<br/> <b>Intervention:</b> physical activity advice plus placebo<br/> <b>Comparison:</b> no physical activity advice plus omega 3 </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no physical activity advice plus omega 3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with physical activity advice plus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐F<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 9 higher<br/> (1.64 higher to 16.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: MFI<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 14.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.4 lower<br/> (4.39 lower to 1.59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI scores ranged from 0 to 84, with higher scores indicating greater fatigue.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBDF Section 1<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 9.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.8 lower<br/> (5.93 lower to 0.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section I scores ranged from 0 to 20, with higher scores indicating greater levels of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: IBDF Section 2<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 34.8</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 15.4 lower<br/> (30.51 lower to 0.29 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBD‐F Section II scores ranged from 0 to 120, with higher scores indicating greater impact of fatigue. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events: assessed with: Medication diary<br/> follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were four reported adverse events in the physical activity advice plus placebo group and fourteen reported adverse events in the no physical activity advice plus omega 3 group, including epigastric pain, diarrhoea, bloating, nausea and vomiting, IBD flare, joint pain, and ankle injury. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were recorded in the medication diary and assessed by the researcher during the 6 follow‐up contact time points. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the number of participants was small, confidence interval was wide and per protocol analyses used. </p> <p><sup>2</sup> Downgraded one level due to high risk of bias for blinding of participants and personnel and blinding of outcome assessments. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with moderately‐to‐severely active disease<br/> <b>Setting:</b> 92 centres in the United States, Europe, Canada, Australia and South Africa<br/> <b>Intervention:</b> adalimumab 40 mg every other week<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adalimumab 40 mg every other week</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐Fatigue<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.3 higher<br/> (1.75 higher to 6.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52, with higher scores indicating less fatigue.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 Vitality<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 54.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.8 higher<br/> (5.1 lower to 10.7 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 172.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.4 higher<br/> (0.53 lower to 21.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>888 per 1,000<br/> (826 to 930) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.44<br/> (0.86 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (56 to 148) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.56<br/> (0.33 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1,000<br/> (39 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.48<br/> (0.26 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the confidence interval was wide and the fatigue data represented the last‐observation‐carried‐forward when a participant had missing value, dropped out or switched to open‐label therapy. </p> <p><sup>2</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>3</sup> Downgraded one level due to serious imprecision as the number of participants was small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> fatigue in inflammatory bowel disease<br/> <b>Setting:</b> 92 centres in the United States, Europe, Canada, Australia and South Africa<br/> <b>Intervention:</b> adalimumab 40 mg weekly<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adalimumab 40 mg weekly</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: FACIT‐Fatigue<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 32.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.5 higher<br/> (0.26 lower to 5.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F scores ranged from 0 to 52 with higher scores indicating less fatigue.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 vitality<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 54.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.2 higher<br/> (4.72 lower to 11.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 172.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.4 higher<br/> (1.63 lower to 20.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>856 per 1,000<br/> (785 to 906) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.08<br/> (0.66 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 per 1,000<br/> (48 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.49<br/> (0.28 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1,000<br/> (24 to 88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.33<br/> (0.15 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>518<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to very serious imprecision as the confidence interval was wide and the fatigue data represented the last‐observation‐carried‐forward when a participant had missing value, dropped out or switched to open‐label therapy. </p> <p><sup>2</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>3</sup> Downgraded one level due to serious imprecision as the number of participants was small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with moderately‐to‐severely active Crohn's disease<br/> <b>Setting:</b> 92 centres in the United States, Europe, Canada, Australia and South Africa<br/> <b>Intervention:</b> adalimumab maintenance<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adalimumab maintenance</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 Vitality<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 54.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3 higher<br/> (4.25 lower to 10.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating better vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: SF‐36 Physical Component Summary<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 47.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.3 higher<br/> (1.3 lower to 3.99 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 physical component summary scores ranged from 0 to 100, with higher scores indicating better physical quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: SF‐36 Mental Component Summary<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 48.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.2 higher<br/> (1.28 lower to 5.68 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SF‐36 mental component summary scores ranged from 0 to 100, with higher scores indicating better mental quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 172.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.9 higher<br/> (0.4 lower to 20.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>873 per 1,000<br/> (817 to 913) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.24<br/> (0.81 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDra<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 per 1,000<br/> (56 to 131) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.53<br/> (0.33 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 56 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 per 1,000<br/> (36 to 93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.40<br/> (0.24 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>2</sup> Downgraded one level due to serious imprecision as the number of events was small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AndoSan compared to placebo for participants with mild‐to‐moderately active Crohn's disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>AndoSan compared to placebo for participants with mild‐to‐moderately active Crohn's disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with mild‐to‐moderately active Crohn's disease<br/> <b>Setting:</b> outpatients from a single centre in Oslo, Norway<br/> <b>Intervention:</b> AndoSan<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with AndoSan</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Total Fatigue score<br/> follow‐up: 21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 16.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.63 lower<br/> (3.51 lower to 0.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total fatigue scores ranged from 0 to 33, with higher scores indicating greater fatigue.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 Vitality<br/> follow‐up: 21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 40.61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.68 higher<br/> (1.64 lower to 9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>2</sup> Downgraded by one level due to high risk of bias for allocation bias (open allocation). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AndoSan compared to placebo for participants with mild‐to‐moderately active Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Ferric maltol compared to placebo for participants in remission or mild‐to‐moderately active Crohn's disease</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ferric maltol compared to placebo for participants in remission or mild‐to‐moderately active Crohn's disease</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants in remission or mild‐to‐moderately active Crohn's disease<br/> <b>Setting:</b> outpatients from 4 centres in Austria, Germany, Hungary and the UK<br/> <b>Intervention:</b> ferric maltol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ferric maltol</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: SF‐36 vitality<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 53.23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.31 lower<br/> (17.15 lower to 1.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 vitality subscale scores ranged from 0 to 100, with higher scores indicating greater vitality (less fatigue). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> assessed with: IBDQ<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life score was 176</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.7 higher<br/> (7.89 lower to 15.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IBDQ scores ranged from 32 to 224, with higher scores indicating better quality of life. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/> assessed with: MedDRA<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>717 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>582 per 1,000<br/> (397 to 749) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.55<br/> (0.26 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> assessed with: MedDRA<br/> follow‐up: mean 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (5 to 202) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.14 to 7.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events<br/> assessed with: MedDRA<br/> follow‐up: 12 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 per 1,000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 per 1,000<br/> (45 to 334) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.69<br/> (0.52 to 5.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Ferric maltol compared to placebo for participants in remission or mild‐to‐moderately active Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Guided stress management compared to conventional medical treatment for participants with Crohn's disease in remission</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Guided stress management compared to conventional medical treatment for participants with Crohn's disease in remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with Crohn's disease in remission<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> guided stress management<br/> <b>Comparison:</b> conventional medical treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional medical treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with guided stress management</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Average frequency of tiredness<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 51.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/> (30.77 lower to 30.77 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average frequency of tiredness was calculated as the number of symptomatic days divided by total reported days x 100. Higher mean scores indicated higher average frequency of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Severity of tiredness<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 higher<br/> (0.39 lower to 0.99 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The severity of tiredness scores ranged from 0 to 3, with higher scores indicating greater severity of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels due to serious imprecision as the number of participants was small and the confidence interval was wide. </p> <p><sup>2</sup> Downgraded by two levels due to high risk of bias for most criteria. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Guided stress management compared to conventional medical treatment for participants with Crohn's disease in remission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012005-tbl-0013"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Self‐directed stress management compared to conventional medical treatment for participants with Crohn's disease in remission</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Self‐directed stress management compared to conventional medical treatment for participants with Crohn's disease in remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with Crohn's disease in remission<br/> <b>Setting:</b> outpatients from a single centre in Spain<br/> <b>Intervention:</b> self‐directed stress management<br/> <b>Comparison:</b> conventional medical treatment </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional medical treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk with self‐directed stress management</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Average frequency symptom (tiredness)<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 51.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 29.6 lower<br/> (58.68 lower to 0.52 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average frequency symptom (tiredness) was calculated as the number of symptomatic days divided by the total reported days x 100. Higher scores indicated greater average frequency of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue<br/> assessed with: Severity of tiredness<br/> follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean fatigue score was 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 lower<br/> (0.98 lower to 0.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of tiredness scores ranged from 0 to 3, with higher scores indicating greater severity of tiredness. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse events ‐ not measured</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide. </p> <p><sup>2</sup> Downgraded by two levels due to high risk of bias for most criteria. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Self‐directed stress management compared to conventional medical treatment for participants with Crohn's disease in remission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/full#CD012005-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adalimumab maintenance versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: SF‐36 Vitality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: SF‐36 PCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: SF‐36 MCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawal due to AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adalimumab maintenance versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adalimumab 40 mg eow versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐ F <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: SF‐36 Vitality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: SF‐36 PCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life: SF‐36 MCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal due to AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adalimumab 40 mg eow versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adalimumab 40 mg weekly versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: SF‐36 vitality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: SF‐36 PCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life: SF‐36 MCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Week 4 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Week 56 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal due to AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adalimumab 40 mg weekly versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">AndoSan versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: Total Fatigue Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Day 14 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐3.51, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Day 21 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐3.46, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: SF‐36 Vitality subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Day 14 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.84 [‐3.78, 11.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Day 21 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [‐3.91, 10.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">AndoSan versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Ferric maltol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: SF‐36 Vitality subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Ferric maltol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Electroacupuncture versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐F <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 8 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: IBDQ‐9 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 8 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Electroacupuncture versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Electroacupuncture versus sham electroacupuncture</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐F <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 8 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Week 16 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: IBDQ‐9 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 8 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Week 16 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Electroacupuncture versus sham electroacupuncture</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Guided stress management versus conventional medical treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: Average frequency symptom (tiredness) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Post‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: Average severity of tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Post‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 12 month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Guided stress management versus conventional medical treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Self‐directed stress management versus conventional medical treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: Average frequency of tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Post‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: Average severity of tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Post‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 12 month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Self‐directed stress management versus conventional medical treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">CBT with therapist support versus fatigue information leaflet only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: IBD‐F Section I <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Month 3 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: IBD‐F Section II <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Month 3 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: UK‐IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Month 3 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">CBT with therapist support versus fatigue information leaflet only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Physical activity advice plus omega 3 versus no physical activity advice plus omega 3</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐F <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: MFI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatigue: IBD‐F Section I <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatigue: IBD‐F Section II <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Physical activity advice plus omega 3 versus no physical activity advice plus omega 3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Physical activity advice plus placebo versus no physical activity advice plus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐F <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: MFI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatigue: IBD‐F Section I <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatigue: IBD‐F Section II <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Physical activity advice plus placebo versus no physical activity advice plus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012005-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Physical activity advice plus placebo versus no physical activity advice plus omega 3</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatigue: FACIT‐F <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue: MFI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatigue: IBD‐F Section I <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatigue: IBD‐F Section II <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: IBDQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Week 12 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Physical activity advice plus placebo versus no physical activity advice plus omega 3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012005.pub2/references#CD012005-tbl-0026">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012005.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012005-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012005-note-0001">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012005-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012005-note-0025">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012005-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012005-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012005-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012005-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012005\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012005\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012005\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012005\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012005\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012005.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012005.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012005.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012005.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012005.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724747330"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012005.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724747334"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012005.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6a5caea31c00',t:'MTc0MDcyNDc0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 